Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. 36,000,000 Series B Shares (without par value) of Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. directly or in the form of American Depositary Shares UNDERWRITING AGREEMENT

Exhibit 1.1

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

36,000,000 Series B Shares (without par value) of

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

directly or in the form of American Depositary Shares

UNDERWRITING AGREEMENT

July 9, 2013

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇

Incorporated

as Representative of the several Underwriters

c/o Merrill Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇

Incorporated

▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

Banco Bilbao Vizcaya Argentaria, S.A.

▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇ ▇/▇

▇▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇

Santander Investment Securities Inc.

▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

Barclays Capital Inc.

▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

▇▇▇▇▇▇ ▇▇▇▇▇▇▇ & Co. LLC

▇▇▇▇ ▇▇▇▇▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

Ladies and Gentlemen:

The shareholder named in Schedule III hereto (the “Selling Shareholder”) of Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., a sociedad anónima bursátil de capital variable (the “Company”) organized under the laws of the United Mexican States (“Mexico”) proposes to sell to the Underwriters named in Schedule II hereto (collectively, the “Underwriters” which term shall also include any underwriter substituted as hereinafter provided in Section 11 hereof), for whom ▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated (the “Representative”) is acting as representative, an aggregate of 36,000,000 outstanding Series B

shares, without par value, of the Company (the “Series B Shares”), directly or in the form of American Depositary Shares (the “ADSs”). The Series B Shares, including any ADSs representing such Series B Shares, to be purchased by the Underwriters as set forth in this Underwriting Agreement (the “Agreement”) are hereinafter called, collectively, the “International Firm Shares.” The Selling Shareholder also proposes to sell to the Underwriters, at the option of the Underwriters and as set forth in this Agreement, an aggregate of not more than an additional 5,400,000 Series B Shares directly or in the form of ADSs (the “International Option Shares,” and together with the International Firm Shares, hereinafter called the “International Shares”). The ADSs are to be evidenced by American Depositary Receipts (the “ADRs”) issued pursuant to a Deposit Agreement, effective as of December 27, 2012 (the “Deposit Agreement”), among the Company, JPMorgan Chase Bank, N.A., as Depositary (the “Depositary”), and all registered holders from time to time of any ADRs issued thereunder. Each reference herein to an ADR shall include the corresponding ADS, and vice versa. Each ADS represents eight (8) Series B Shares.

It is understood that the Company and the Selling Shareholder are concurrently entering into a Contrato de Colocación (the “Mexican Underwriting Agreement,” together with this Agreement, the “Global Underwriting Agreements”) providing for the sale by the Selling Shareholder to ▇▇▇▇▇▇▇ ▇▇▇▇▇ México, S.A. de C.V., Casa de Bolsa, Casa de Bolsa BBVA Bancomer, S.A. de C.V., Grupo Financiero BBVA Bancomer and Casa de Bolsa Santander, S.A. de C.V., Grupo Financiero Santander México (collectively, the “Mexican Underwriters”), of an aggregate of 24,000,000 Series B Shares (said shares to be sold by the Selling Shareholder pursuant to the Mexican Underwriting Agreement being hereinafter called the “Mexican Base Shares”) and providing for the grant to the Mexican Underwriters of an option to purchase from the Selling Shareholder up to 3,600,000 additional Series B Shares (the “Mexican Option Shares,” and together with the Mexican Base Shares, the “Mexican Shares,” and together with the International Shares, the “Global Shares”).

It is further understood and agreed that the Mexican Underwriters and the Underwriters (collectively, the “Global Underwriters”) have entered into an intersyndicate agreement (the “Intersyndicate Agreement”), pursuant to which, among other things, the Mexican Underwriters may purchase from the Underwriters a portion of the International Shares to be sold pursuant to this Agreement and the Underwriters may purchase from the Mexican Underwriters a portion of the Mexican Shares to be sold pursuant to the Mexican Underwriting Agreement. In addition, under the Intersyndicate Agreement, the Mexican Underwriters and the Underwriters have agreed to the terms for the concurrent, but independent, purchase of the International Option Shares and the Mexican Option Shares, and to conduct stabilization transactions.

The use of the neuter in this Agreement shall include the feminine and masculine wherever appropriate. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 6 of the Registration Statement on Form F-3 (“Form F-3”) which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus or the Final Prospectus, as the case may be; and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement,

the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus or the Final Prospectus, as the case may be, deemed to be incorporated therein by reference. Certain terms used in this Agreement are defined in Section 25 hereof.

1. Representations and Warranties of the Company. The Company represents and warrants to, and agrees with, each Underwriter as of the date hereof as set forth below in this Section 1.

(a) The Company meets the requirements for use of Form F-3 under the Act and has prepared and filed with the Commission a registration statement, as defined in Rule 405 (No. 333-188624) on Form F-3, including a related Base Prospectus, for registration under the Act of the offering and sale of the International Shares. Such Registration Statement, including any amendments or supplements thereto filed prior to the Execution Time, has become effective under the Act. The Company may have filed with the Commission, as part of an amendment to the Registration Statement or pursuant to Rule 424(b), one or more preliminary prospectus supplements relating to the International Shares, each of which has previously been furnished to the Representative. The Company will file with the Commission a Final Prospectus relating to the International Shares in accordance with Rule 424(b). As filed, such Final Prospectus shall contain all information required by the Act and the rules thereunder, and, except to the extent the Representative shall agree in writing to a modification, shall be in all substantive respects in the form furnished to the Representative prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain only such specific additional information and other changes (beyond that contained in the Base Prospectus and any Preliminary Prospectus) as the Company has advised the Representative, prior to the Execution Time, will be included or made therein. The Registration Statement, at the Execution Time, meets the requirements set forth in Rule 415(a)(1)(x). It is understood that two forms of prospectuses are to be used in connection with the offering and sale of the Global Shares: one form of prospectus relating to the International Shares, which are to be offered and sold outside of Mexico, and one form of prospectus relating to the Mexican Shares, which are to be offered and sold in Mexico.

(b) On each Effective Date, the Registration Statement did, and when the Final Prospectus is first filed in accordance with Rule 424(b) and Rule 430A and on the Closing Date (as defined herein) and on any date on which International Option Shares are purchased, if such date is not the Closing Date (a “Settlement Date”), the Final Prospectus (and any amendments or supplements thereto) will comply in all material respects with the applicable requirements of the Act and the Exchange Act and the respective rules thereunder; on each Effective Date and at the Execution Time, the Registration Statement did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the date of any filing pursuant to Rule 424(b) and on the Closing Date and any Settlement Date and at any time when a prospectus is required (or, but for the provisions of Rule 172, would be required) by applicable law to be delivered in connection with sales of International Shares, the Final Prospectus (together with any amendments or supplements thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the

statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Final Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Underwriter through the Representative specifically for inclusion in the Registration Statement or the Final Prospectus (or any amendments or supplement thereto), it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of the information described as such in Section 10(c) hereof; and provided, further that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Final Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to the Selling Shareholder furnished in writing by or on behalf of the Selling Shareholder specifically for inclusion in the Registration Statement or the Final Prospectus (or any amendments or supplement thereto), it being understood and agreed that the only such information furnished by or on behalf of the Selling Shareholder consists of the information described as such in Section 10(b). The Company has complied, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement has been issued and, to the knowledge of the Company, no proceeding for that purpose has been instituted or threatened by the Commission or by the securities authority of any jurisdiction. No order preventing or suspending the use of the Final Prospectus has been issued and, to the knowledge of the Company, no proceeding for that purpose has been instituted by the Commission or by the securities authority of any jurisdiction.

(c) (i) The Disclosure Package and the price per share to the public, the number of International Firm Shares and the number of International Option Shares to be included on the cover page of the Final Prospectus, when taken together as a whole and (ii) each electronic road show material when taken together as a whole with the Disclosure Package and the price per share to the public, the number of International Firm Shares and the number of International Option Shares to be included on the cover page of the Final Prospectus, as of the Execution Time, does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from the Disclosure Package based upon and in conformity with (i) written information furnished to the Company by any Underwriter through the Representative specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of the information described as such in Section 10(c) hereof, and (ii) any information relating to the Selling Shareholder furnished in writing by or on behalf of the Selling Shareholder expressly for use therein, it being understood and agreed that the only such information furnished by or on behalf of the Selling Shareholder consists of the information described as such in Section 10(b).

(d) (i) At the earliest time after the filing of the Registration Statement that the Selling Shareholder made a bona fide offer (within the meaning of Rule 164(h)(2)) of the International Shares and (ii) as of the Execution Time (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an Ineligible

Issuer (as defined in Rule 405), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer.

(e) Each Issuer Free Writing Prospectus does not include any information that conflicts with the information contained in the Registration Statement or the Final Prospectus, including any document incorporated therein by reference, any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. The preceding sentence does not apply to statements in or omissions from the Issuer Free Writing Prospectus based upon and in conformity with (i) written information furnished to the Company by any Underwriter through the Representative specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf of any Underwriter consists of the information described as such in Section 10(c) hereof, and (ii) any information relating to the Selling Shareholder furnished in writing by or on behalf of the Selling Shareholder expressly for use therein, it being understood and agreed that the only such information furnished by or on behalf of the Selling Shareholder consists of the information described as such in Section 10(b).

(f) The Base Prospectus and each Preliminary Prospectus delivered to the Underwriters for use in connection with the sale of the International Shares complied when so filed in all material respects with the Act and such Base Prospectus and each such Preliminary Prospectus was, and the Final Prospectus delivered to the Underwriters for use in connection with this offering will be, identical to the electronically transmitted copies thereof filed with the Commission pursuant to ▇▇▇▇▇, except to the extent permitted by Regulation S-T under the Act.

(g) All documents filed by the Company pursuant to Sections 12, 13, 14 or 15 of the Exchange Act and incorporated or deemed to be incorporated by reference into the Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Disclosure Package or the Final Prospectus, when they became effective or were filed with the Commission, as the case may be, complied in all material respects with the requirements of the Act or the Exchange Act, as applicable and were filed on a timely basis with the Commission, and none of such documents contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(h) The Company has been duly incorporated and is validly existing as a sociedad anónima bursátil de capital variable and each of its subsidiaries has been duly organized and is validly existing under the laws of Mexico as a corporation under the laws of the jurisdiction in which it is chartered or organized. Each of the Company and its subsidiaries have full corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business as described in the Disclosure Package and the Final Prospectus, and is duly qualified to do business as a foreign corporation where it does business as such and is in good standing, if applicable, under the laws of each jurisdiction which requires such qualification, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect, and except as set forth in or contemplated in the Disclosure Package and the Final Prospectus (exclusive of any amendment or supplement thereto).

(i) All the outstanding shares of capital stock or other ownership interests of each subsidiary of the Company have been duly and validly authorized and issued and are fully paid and non-assessable, and, except as otherwise set forth in the Registration Statement, Disclosure Package and the Final Prospectus, all outstanding shares of capital stock or other ownership interests of the Company’s subsidiaries are owned by the Company either directly or through wholly owned subsidiaries free and clear of any perfected security interest or any other security interests, claims, mortgages, pledges, liens, encumbrances or other title retention arrangements or restrictions of any kind (collectively, “Liens”), except for Liens as in the individual or the aggregate could not reasonably be expected to result in a Material Adverse Effect. Except as set forth in the Registration Statement, Disclosure Package and the Final Prospectus, there are no outstanding options, warrants or other rights to purchase, agreements or other obligations to issue, or rights to convert any obligations into or exchange any securities or interests for capital stock or other ownership interests of any subsidiary of the Company.

(j) The Company’s authorized equity capitalization is as set forth in the Disclosure Package and the Final Prospectus; the capital stock of the Company conforms in all material respects to the description thereof contained in the Disclosure Package and the Final Prospectus; the Global Shares and all other outstanding shares of capital stock of the Company, including the Series B Shares, have been duly authorized and validly issued, are fully subscribed to, paid for and nonassessable under Mexican law, and are free and clear of any Liens; the Global Shares are duly listed for quotation, and admitted and authorized, for trading on the NASDAQ Stock Market LLC (“NASDAQ”) or on the Mexican Stock Exchange (Bolsa Mexicana de Valores, S.A.B. de C.V.), as the case may be; the certificates for the International Shares are in valid and sufficient form; the holders of outstanding shares of capital stock of the Company are not entitled to preemptive or other similar rights to subscribe for the International Shares; except as set forth in the Disclosure Package and the Final Prospectus, no options, warrants or other rights to purchase, agreements or other obligations to issue, or rights to convert any obligations into or exchange any securities for, shares of capital stock of or ownership interests in the Company are outstanding. No holders of the Global Shares will be subject to personal liability for obligations of the Company solely by reason of being such a holder.

(k) There is no franchise, contract or other document of a character required to be described in the Registration Statement, the ADR Registration Statement (as defined below), the Disclosure Package or the Final Prospectus, or to be filed as an exhibit thereto, which is not described or filed as required (and the Preliminary Prospectus used most recently prior to the Execution Time contains in all material respects the same description of the foregoing matters contained in the Final Prospectus); and, subject to the same provisos in Section 1(b) above, the statements included or incorporated by reference in the Disclosure Package and the Final Prospectus under the headings “Our Company,” “Description of Our Capital Stock,” “Description of the American Depositary Shares.” “Taxation,” “Plan of Distribution” and the statements in the Form 20-F (as defined below) under the captions “Item 3. Key Information – Risk Factors – Risk Related to Our Shareholders – Aeroinvest, S.A. de C.V. (Aeroinvest), and Servicios de Tecnología Aeroportuaria, S.A. de C.V. (SETA), control our management, and their interests may differ from those of other stockholders” and “– If SETA, one of our principal shareholders, should sell or otherwise transfer all or a portion of our Series BB shares that it holds our operations could be adversely affected,” “– Risk Related to Our ADSs – You may not

be entitled to participate in future preemptive rights offerings” and “– Holders of ADSs are not entitled to attend shareholders’ meetings, and they may only vote through the depositary,” “Item 6. Directors, Senior Management and Employees – Committees,” “Item 8. Financial Information – Legal Proceedings,” “Item 10. Additional Information – Taxation” as such statements summarize legal matters, agreements, documents or proceedings discussed therein, fairly summarize such legal matters, agreements, documents or proceedings in all material respects.

(l) Each of this Agreement and the Deposit Agreement has been duly authorized, executed and delivered by the Company.

(m) The Company is not and, after giving effect to the offering and sale of the Global Shares thereof as described in the Disclosure Package and the Final Prospectus, will not be an “investment company” as defined in the Investment Company Act of 1940, as amended.

(n) No consent, approval, authorization, filing with, registration, or order of any court or governmental agency or body is necessary or required for the performance by the Company of its obligations hereunder in connection with the offering or sale of the Global Shares hereunder or the consummation of the transactions contemplated herein or in the Deposit Agreement, except (i) such as have been obtained or made under the Act and such as may be required under the blue sky laws of any jurisdiction, the NASDAQ rules and the rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”) in connection with the purchase and distribution of the Global Shares by the Underwriters in the manner contemplated herein and in the Registration Statement, Disclosure Package and the Final Prospectus, the Ley del ▇▇▇▇▇▇▇ de Valores and regulations thereunder or the regulations of the Mexican Stock Exchange, or any laws of jurisdictions outside of Mexico and the United States in which the Global Shares are offered and sold or (ii) as otherwise set forth in Section 1(ss) hereof.

(o) None of the execution, delivery and performance by the Company of this Agreement or the Deposit Agreement, the sale of the Global Shares, or the consummation of the transactions herein or therein contemplated and as described in the Disclosure Package and the Final Prospectus, or the fulfillment of the terms hereof and thereof by the Company does or will conflict with, result in a breach or violation of, or imposition of any Lien upon any property or assets of the Company or any of its subsidiaries pursuant to, (i) the acta constitutiva, estatutos sociales or comparable constituent documents of the Company or any of its subsidiaries, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject, except for such breach, violation or imposition which, individually or in the aggregate, would not have a Material Adverse Effect and would not have a material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby, or (iii) any statute, law, rule, regulation, judgment, order or decree applicable to the Company or any of its subsidiaries of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its subsidiaries or any of its or their properties.

(p) No holders of securities of the Company have rights to the registration of such securities under the Registration Statement.

(q) The consolidated historical financial statements and schedules, including the notes thereto, of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Disclosure Package and the Final Prospectus, present fairly the financial condition, results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form with the applicable accounting requirements of the Act and the Exchange Act and have been prepared in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The selected financial data set forth under the caption “Item 3. Key Information – Selected Financial Data” in the Company’s most recent annual report on Form 20-F as incorporated by reference in the Registration Statement (the “Form 20-F”) and under the caption “Selected Consolidated Financial Data” in the Disclosure Package, the Final Prospectus and the Registration Statement fairly present, on the basis stated in the Disclosure Package, the Final Prospectus and the Registration Statement, the information included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the Disclosure Package or the Final Prospectus under the Act and the Exchange Act. All disclosures contained in the Registration Statement, the Disclosure Package or the Final Prospectus, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Act and Item 10 of Regulation S-K of the Act, to the extent applicable.

(r) No action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries or its or their property is pending or, to the best knowledge of the Company, threatened that (i) could reasonably be expected to have a material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby or (ii) could reasonably be expected to have a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto).

(s) Each of the Company and each of its subsidiaries owns or leases all such properties as are necessary to the conduct of its operations as presently conducted.

(t) Except as otherwise disclosed in the Final Prospectus, each of the Company and its subsidiaries owns or possesses all inventions, patent applications, patents, trademarks (both registered and unregistered), tradenames, service names, copyrights, trade secrets and other proprietary information described in the Final Prospectus as being owned or licensed by it or which is necessary for the conduct of, or material to, its businesses (collectively, the “Intellectual Property”), and the Company is unaware of any claim to the contrary or any challenge by any other person to the rights of the Company or any of its subsidiaries with respect to the Intellectual Property or any claims that the Company or any of its subsidiaries has infringed or is infringing the intellectual property of a third party, except when any such claim,

challenge or infringement would not, individually or in the aggregate, have a Material Adverse Effect.

(u) Neither the Company nor any of its subsidiaries is in violation or default of (i) any provision of its acta constitutiva, estatutos sociales or comparable constituent documents, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which it is a party or bound or to which its property is subject, or (iii) any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or such subsidiary or any of its properties, as applicable, except in the case of clauses (ii) and (iii) in this paragraph any violation or default which would not have a Material Adverse Effect.

(v) Galaz, Yamazaki, ▇▇▇▇ ▇▇▇▇▇▇▇, S.C., member firm of Deloitte Touche Tohmatsu Limited, who have certified the financial statements and supporting schedules of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Disclosure Package and the Final Prospectus, and delivered their report with respect to the audited consolidated financial statements and schedules included or incorporated by reference in the Registration Statement, the Disclosure Package and the Final Prospectus, are independent public accountants with respect to the Company within the meaning of the Act and the applicable published rules and regulations thereunder.

(w) There are no stamp or other issuance or transfer taxes or duties or other similar fees or charges required to be paid in connection with (A) the execution and delivery of this Agreement or the sale by the Selling Shareholder of the Global Shares, other than fees paid to the Comisión Nacional Bancaria y de Valores (the “CNBV”) in connection with the approval of the public offering in Mexico and the registration of the Global Shares or (B) the deposit with the Depositary of the Underlying Shares against issuance of the ADRs evidencing the ADSs.

(x) Each of the Company and its subsidiaries has filed all Mexican and applicable non-Mexican federal, state and local tax returns that are required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto)) and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such tax, assessment, fine or penalty that is currently being contested in good faith or as would not have a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto). The Company has made adequate charges, accruals and reserves in accordance with IFRS in the applicable financial statements referred to in Section 1(q) hereof in respect of all U.S., Mexican and other foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined.

(y) No labor dispute with the employees of the Company or any of its subsidiaries exists or is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, that could have a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto).

(z) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged and in the territories in which such businesses are conducted; all material policies of insurance and fidelity or surety bonds insuring the Company or any of its subsidiaries or their respective businesses, assets, employees, officers and directors are in full force and effect; the Company and its subsidiaries are in compliance with the terms of such policies and instruments in all material respects; and there are no material claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; neither the Company nor any such subsidiary has been refused any insurance coverage sought or applied for; and neither the Company nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto).

(aa) No significant subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends or distributions to the Company or any of its subsidiaries, as applicable, from making any other distribution on such subsidiary’s capital stock or equity interests, from repaying to the Company or any of its subsidiaries any loans or advances to such subsidiary from the Company or any of its subsidiaries or from transferring any of such subsidiary’s property or assets to the Company or any other subsidiary of the Company, except as described in or contemplated by the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto).

(bb) The Company and each subsidiary has conducted and is conducting its business in compliance with all applicable U.S. and Mexican laws, rules and regulations, except where the failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations (including, without limitation, airport concessions) issued by all applicable authorities necessary to conduct their respective businesses, except where the failure to possess such license, certificate, permit, concession or other authorization would not have a Material Adverse Effect, and neither the Company nor any such subsidiary has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such license, certificate, concession, authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, except as set forth in or

contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto).

(cc) The Company and each of its subsidiaries maintain a system of internal accounting controls that is in compliance with the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act and is sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and its subsidiaries’ internal controls over financial reporting are effective and, except as set forth in the Form 20-F, the Company and its subsidiaries are not aware of any material weakness in their internal controls over financial reporting.

(dd) The Company and its subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s applicable rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management, including to the Company’s chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

(ee) The Company has not taken, nor will the Company take, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the International Shares.

(ff) Except as described in the Registration Statement, the Disclosure Package and the Final Prospectus or would not, individually or in the aggregate, result in a Material Adverse Effect, (i) neither the Company nor any of its subsidiaries is in violation of any Mexican and applicable non-Mexican federal, state, local or foreign statute, law, rule, regulation, ordinance, code, official standards (normas tecnicas), policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all permits, authorizations

and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (iii) there are no pending or, to the best knowledge of the Company and its subsidiaries, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, Liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv) to the best knowledge of the Company and its subsidiaries, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.

(gg) In the ordinary course of its business, the Company periodically reviews the effect of Environmental Laws on the business, operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties). On the basis of such review and the amount of its established reserves, the Company has reasonably concluded that such associated costs and liabilities would not, individually or in the aggregate, result in a Material Adverse Effect, except as set forth in or contemplated in the Registration Statement, the Disclosure Package and the Final Prospectus.

(hh) There is and has been no failure on the part of the Company and any of the Company’s directors or officers, in their capacities as such, to comply with any provision of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002 and the rules and regulations promulgated in connection therewith (the “▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act”), including the establishment and maintenance of disclosure controls and procedures, Section 402 related to loans and Sections 302 and 906 related to certifications.

(ii) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other individual or entity (“Person”) acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such Persons of the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”) or any other applicable law, rule or regulation of any locality of similar purpose and scope, including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA or such similar and applicable laws, rules or regulations and the Company, its subsidiaries and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and such similar and applicable laws, rules and regulations, and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

(jj) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the U.S. Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of any jurisdiction and the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

(kk) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or any of its subsidiaries is a Person, or is owned or controlled by a Person that is, currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control, the U.S. Department of Commerce, the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the International Shares, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions. For the past five years, neither the Company nor any of its subsidiaries has knowingly engaged in, and is not now knowingly engaged in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

(ll) The Company has no “significant subsidiaries” (as such term is defined under Rule 1-02(w), subsections 1 or 2, of Regulation S-X under the Act) other than as set forth on Schedule V attached hereto.

(mm) The Company and its subsidiaries are subject to civil and commercial law and to suit and neither the Company nor any of its subsidiaries nor any of their respective properties, assets or revenues have any right of immunity, on the grounds of sovereignty or otherwise, from any legal action, suit or proceeding, from the giving of any relief in any such legal action, suit or proceeding, from setoff or counterclaim, from the jurisdiction of any Mexican, New York State or U.S. federal court or any court of any jurisdiction in which the Company or any of its subsidiaries owns or leases property or assets, from service of process, attachment upon or prior to judgment, or attachment in aid of execution of judgment, or from execution or enforcement of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court, with respect to their respective obligations or liabilities or any other matter under or arising out of or in connection with the Global Underwriting Agreements; and, to the extent that the Company, any of its subsidiaries or any of their respective properties, assets or revenues may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings may at any time be

commenced, the Company and its subsidiaries have waived or will waive such right to the extent permitted by law and has consented to such relief and enforcement as provided in the Global Underwriting Agreements.

(nn) The Company and the Depositary filed with the Commission on December 14, 2012, a registration statement on Form F-6 (No. 333-185511) and a related prospectus, for the registration under the Act of the ADSs evidenced by ADRs. The Company may have filed one or more amendments thereto, each of which has previously been furnished to you. Such ADR Registration Statement on the Closing Date will conform in all material respects to the applicable requirements of the Act and the rules and regulations thereunder and, at the time the ADR Registration Statement, any post-effective amendment or amendments thereto became or becomes effective, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

(oo) Upon issuance by the Depositary of ADSs evidenced by ADRs against deposit of Underlying Shares in accordance with the provisions of the Deposit Agreement, such ADRs will be duly and validly issued and Persons in whose names the ADRs are registered will be entitled to the rights specified in the ADRs and in the Deposit Agreement; and upon the sale and delivery to the Underwriters of the International Shares, and payment therefor, pursuant to this Agreement, the Underwriters will acquire good, marketable and valid title to such International Shares, free and clear of any Liens.

(pp) All dividends and other distributions declared and payable on the International Shares may under current Mexican laws and regulations be paid, directly or indirectly, to the Depositary and to the holders of such International Shares, as the case may be, in Mexican pesos that may be converted into foreign currency that may be freely transferred out of Mexico in accordance with the Deposit Agreement; and, except as set forth in the Disclosure Package and the Final Prospectus, all such dividends and other distributions made to holders of International Shares who are non-residents of Mexico for tax purposes and do not hold the International Shares or a beneficial interest therein in connection with the conduct of a trade or business in Mexico through a permanent establishment for tax purposes in Mexico are not subject to Mexican withholding or other taxes under current Mexican laws and regulations and are otherwise free and clear of any other tax, duty, withholding or deduction imposed on such holder in Mexico.

(qq) The Company was not in 2011 and 2012 a Passive Foreign Investment Company (“PFIC”) within the meaning of Section 1297 of the United States Internal Revenue Code of 1986, as amended, and does not expect to become a PFIC in 2013.

(rr) The Company is not a “foreign personal holding company” within the meaning of the United States Internal Revenue Code of 1986, as amended.

(ss) A request for authorization of the public offering of the Mexican Shares in Mexico was filed with the CNBV, and the CNBV has authorized the public offering of the Mexican Shares within Mexico. Such CNBV authorization is in full force and effect as of the

date hereof and will be in full force and effect at the time of purchase and on the Closing Date and on any Settlement Date.

(tt) Any certificate signed by any officer of the Company and delivered to the Representative or counsel for the Underwriters in connection with the offering of the International Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to each Underwriter.

2. Representations and Warranties of the Selling Shareholder. The Selling Shareholder represents and warrants to, and agrees with, each Underwriter as of the date hereof as set forth below in this Section 2.

(a) This Agreement has been duly authorized, executed and delivered by the Selling Shareholder.

(b) No consent, approval, authorization, filing with, registration, or order of any court or governmental agency or body is necessary or required for the performance by the Selling Shareholder of its obligations hereunder in connection with the offering or sale of the Global Shares hereunder or the consummation of the transactions contemplated herein or in the Deposit Agreement, except (i) such as have been obtained or made under the Act and such as may be required under the blue sky laws of any jurisdiction in connection with the purchase and distribution of the Global Shares by the Underwriters in the manner contemplated herein and in the Registration Statement, Disclosure Package and the Final Prospectus, the Ley del ▇▇▇▇▇▇▇ de Valores and regulations thereunder or the regulations of the Mexican Stock Exchange, or any laws of jurisdictions outside of Mexico and the United States in which the Global Shares are offered and sold or (ii) as otherwise set forth in Section 1(ss) hereof.

(c) None of the execution, delivery and performance by the Selling Shareholder of this Agreement, the sale of the International Shares, or the consummation of the transactions herein or therein contemplated and as described in the Disclosure Package and the Final Prospectus, or the fulfillment of the terms hereof by the Selling Shareholder does and will conflict with, result in a breach or violation of, or imposition of any Lien upon any property or assets of the Selling Shareholder pursuant to, (i) the acta constitutiva, estatutos sociales or comparable constituent documents of the Selling Shareholder (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Selling Shareholder is a party or bound or to which its or their property is subject, or (iii) any statute, law, rule, regulation, judgment, order or decree applicable to the Selling Shareholder of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Selling Shareholder or any of its properties, except, in the case of clauses (ii) and (iii) above, for such conflicts, breaches, violations or impositions which would not have a Material Adverse Effect and would not have a material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby.

(d) The Selling Shareholder is and on the Closing Date will be the record and beneficial owner of the Global Shares, and has and on the Closing Date will have

good and valid title to the Global Shares to be delivered by the Selling Shareholder on the Closing Date, free and clear of all Liens, and full right, power and corporate authority to enter into and perform its obligations under this Agreement and to sell, assign, transfer and deliver the Global Shares to be delivered by the Selling Shareholder on the Closing Date hereunder; and upon the delivery of and payment for the Global Shares on the Closing Date hereunder the Underwriters will acquire good and valid title to the Global Shares to be delivered by the Selling Shareholder on the Closing Date, free and clear of all Liens.

(e) Upon deposit of the International Shares to be sold by the Selling Shareholder and payment therefor pursuant to this Agreement, valid title to such International Shares will be passed in accordance with the Deposit Agreement to the Depositary who has received deposit of such International Shares without notice of an adverse claim, free and clear of any Liens. Upon payment of the purchase price for the ADSs to be sold by the Selling Shareholder pursuant to this Agreement, delivery of such ADSs, as directed by the Underwriters, to Cede & Co. (“Cede”) or such other nominee as may be designated by The Depository Trust Company (“DTC”), registration of such ADSs in the name of Cede or such other nominee, and the crediting of such ADSs on the books of DTC to securities accounts (within the meaning of Section 8-501(a) of the New York Uniform Commercial Code (the “UCC”) of the Underwriters (assuming that neither DTC nor any such Underwriter has notice of any “adverse claim,” within the meaning of Section 8-105 of the UCC, to such ADSs), (i) under Section 8-501 of the UCC, the Underwriters will acquire a valid “security entitlement” in respect of such ADSs, and (ii) no action (whether framed in conversion, replevin, constructive trust, equitable lien, or other theory) based on any “adverse claim,” within the meaning of Section 8-102 of the UCC, to such ADSs may be asserted against the Underwriters with respect to such security entitlement; for purposes of this representation, the Selling Shareholder may assume that when such payment, delivery and crediting occur, (x) such ADSs will have been registered in the name of Cede or another nominee designated by DTC, in each case on the Company’s share registry in accordance with its charter and by-laws and applicable law, (y) DTC will be registered as a “clearing corporation” within the meaning of Section 8-102 of the UCC and (z) appropriate entries to the accounts of the several Underwriters on the records of DTC will have been made pursuant to the UCC.

(f) The Selling Shareholder has not taken, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the International Shares.

(g) On each Effective Date, the Registration Statement did, and when the Final Prospectus is first filed in accordance with Rule 424(b) and Rule 430A and on the Closing Date and on any Settlement Date, the Final Prospectus (and any amendments or supplements thereto) will comply in all material respects with the applicable requirements of the Act and the Exchange Act and the respective rules thereunder; on each Effective Date and at the Execution Time, the Registration Statement did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading; at the Execution Time, the Disclosure Package does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein not misleading; and on the date of any filing

pursuant to Rule 424(b) and on the Closing Date and any Settlement Date, the Final Prospectus (together with any amendments or supplements thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the representations and warranties set forth in this Section 2(g) apply only to statements or omissions regarding the information furnished by and relating to the Selling Shareholder specifically for inclusion therein, it being understood and agreed that the only such information furnished by the Selling Shareholder consists of the information described as such in Section 10(b) hereof.

(h) The Selling Shareholder has not prepared or had prepared on its behalf or used or referred to, any Issuer Free Writing Prospectus, and has not distributed any written materials in connection with the offer or sale of the International Shares.

(i) The Selling Shareholder has no reason to believe that the representations and warranties of the Company contained in Section 1 of this Agreement are not true and correct, is familiar with the Disclosure Package, the Registration Statement and the ADR Registration Statement and has no knowledge of any material fact, condition or information not disclosed in the Disclosure Package, the Registration Statement and the ADR Registration Statement that, in the individual or the aggregate, would reasonably be expected to result in a Material Adverse Effect.

(j) The sale of the International Shares by the Selling Shareholder pursuant to this Agreement is not and will not be prompted by any material non-public information concerning the Company that is not set forth in the Registration Statement, Disclosure Package or the Final Prospectus, or any amendment or supplement thereto.

(k) The Selling Shareholder does not have any registration or other similar rights to have any equity or debt securities registered for sale by the Company under the Registration Statement or included in the offering contemplated by this Agreement.

(l) There are no actions, suits, claims, investigations or proceedings pending or, to the Selling Shareholder’s knowledge, threatened or contemplated to which the Selling Shareholder or any of its subsidiaries, if any, or any of their respective directors or officers is or would be a party or of which any of their respective properties is or would be subject at law or in equity, before or by any Mexican and non-Mexican federal or state governmental or regulatory commission, board, body, authority or agency seeking to prevent consummation of the transactions contemplated in this Agreement or performance by the Selling Shareholder of its obligations hereunder.

(m) The Selling Shareholder nor any of its affiliates directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with any member firm of FINRA or is a Person associated with a member (within the meaning of the FINRA by-laws) of FINRA.

(n) Any certificate signed by any officer of the Selling Shareholder

and delivered to the Representative or counsel for the Underwriters in connection with the offering of the International Shares shall be deemed a representation and warranty by the Selling Shareholder, as to matters covered thereby, to each Underwriter.

3. Purchase and Sale.

(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Selling Shareholder agrees to sell to each Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Selling Shareholder, at the purchase price set forth in Schedule I hereto, the number of International Firm Shares set forth opposite such Underwriter’s name in Schedule II hereto.

(b) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Selling Shareholder hereby grants an option to the several Underwriters, at the direction of the Representative, to purchase, severally and not jointly, up to the number of International Option Shares set forth in Schedule I hereto at the same purchase price per share as the Underwriters shall pay for the International Firm Shares, less an amount per share equal to any dividends or distributions declared by the Company and payable on the International Firm Shares but not payable on the International Option Shares. Said option may be exercised in whole or in part at any time on or before the 30th day after the date of the pricing of the Global Shares upon written notice by the Representative to the Selling Shareholder setting forth the number of International Option Shares as to which the several Underwriters are exercising the option and the Settlement Date. The number of International Option Shares to be purchased by each Underwriter shall be the same percentage of the total number of International Option Shares to be purchased by the several Underwriters as such Underwriter is purchasing of the International Firm Shares, subject to such adjustments as the Representative in the Representative’s absolute discretion shall make to eliminate any fractional shares.

4. Delivery and Payment. Delivery of and payment for the International Firm Shares and the International Option Shares (if the option provided for in Section 3(b) hereof shall have been exercised on or before the third Business Day immediately preceding the Closing Date) shall be made on the date and at the time specified in Schedule I hereto or at such time on such later date not more than three Business Days after the foregoing date as the Representative shall designate, which date and time may be postponed by agreement between the Representative and the Selling Shareholder or as provided in Section 11 hereof (such date and time of delivery and payment for the International Shares being herein called the “Closing Date”). Delivery of the International Shares shall be made to the Representative for the respective accounts of the several Underwriters against payment by the several Underwriters through the Representative or as otherwise agreed between the Representative and the Selling Shareholder of the purchase price thereof to or upon the order of the Selling Shareholder by wire transfer payable in same-day funds to an account specified by the Selling Shareholder. Delivery of the International Firm Shares and the International Option Shares shall be made through the facilities of DTC unless the Representative shall otherwise instruct.

If the option provided for in Section 3(b) hereof is exercised after the third Business Day immediately preceding the Closing Date, the Selling Shareholder will deliver

the International Option Shares to the Representative on the date specified by the Representative (which shall be within three Business Days after exercise of said option) for the respective accounts of the several Underwriters, against payment by the several Underwriters through the Representative or as otherwise agreed between the Representative and the Selling Shareholder of the purchase price thereof to or upon the order of the Selling Shareholder by wire transfer payable in same-day funds to an account specified by the Selling Shareholder. If settlement for the International Option Shares occurs after the Closing Date, the Selling Shareholder will deliver to the Representative on the Settlement Date for the International Option Shares, and the obligation of the Underwriters to purchase the International Option Shares shall be conditioned upon receipt of, supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and letters delivered on the Closing Date pursuant to Section 8 hereof.

The Underwriters may elect to cause the Selling Shareholder to deposit on their behalf all or any of the Series B Shares to be purchased by them hereunder with the Mexican custodian for the Depositary, through the systems of S.D. Indeval Institución para el Depósito de Valores, S.A. de C.V. (“Indeval”), in accordance with Mexican regulations and the provisions of the Deposit Agreement against the issuance of ADSs. The ADR certificates evidencing the International Shares shall be registered in such names and in such denominations as the Representative may request not less than one full Business Day prior to the applicable Closing Date.

It is understood and agreed that the Closing Date hereunder shall occur simultaneously with the “Closing Date” under the Mexican Underwriting Agreement, and that the Settlement Date for any International Option Shares occurring after the Closing Date hereunder, shall occur simultaneously with the settlement date under the Mexican Underwriting Agreement for any Mexican Option Shares occurring after the Closing Date hereunder.

5. Offering by Underwriters. It is understood that the several Underwriters propose to offer the International Shares for sale to the public as set forth in the Final Prospectus.

6. Further Agreements of the Company. The Company covenants and agrees with the several Underwriters that:

(a) Prior to the termination of the offering of the International Shares, the Company will comply with the requirements of Rule 430A and Rule 433 and will not file any amendment of the Registration Statement or any supplement, amendment or revision (including the Final Prospectus or any Preliminary Prospectus) to the Base Prospectus, any Issuer Free Writing Prospectus or the ADR Registration Statement unless the Company has furnished to the Representative a copy for the Representative’s review prior to filing and will not file or use any such proposed amendment or supplement to which the Representative reasonably object. The Company will cause the Final Prospectus, properly completed, and any supplement thereto to be filed in a form approved by the Representative with the Commission pursuant to the applicable paragraph of Rule 424(b) within the time period prescribed (without reliance on Rule 424(b)(8)) and will provide evidence satisfactory to the Representative of such timely filing (or a post-effective amendment providing such information shall have been filed and declared effective in accordance with the requirements of Rule 430A). The Company will promptly advise the Representative in writing (i) when the Registration Statement, the ADR Registration Statement or any post-effective amendment to the Registration Statement, shall have been filed or become effective, or when any Preliminary Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus or any amendment or supplement thereto shall have been filed, (ii) of the receipt of any comments from the Commission (together with a copy of any comment letters and any transcript of oral comments and any written responses thereto), (iii) of any request by the Commission or its staff for any amendment to the Registration Statement, the ADR Registration Statement or any amendment or supplement to any Preliminary Prospectus or the Final Prospectus, or any document incorporated by reference therein or any Issuer Free Writing Prospectus or for any additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or the ADR Registration

Statement or of any order preventing or suspending the use of any Preliminary Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus or any amendment or supplement thereto, or of any notice objecting to their use or the institution or threatening of any proceeding for that purpose, (v) of the receipt by the Company of any notification with respect to the suspension of the qualification of the International Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes, or of any examination pursuant to Section 8(e) of the Act concerning the Registration Statement and (vi) if the Company becomes the subject of a proceeding under Section 8A of the Act in connection with the offering of the International Shares. The Company will use its reasonable best efforts to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration Statement, the ADR Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or the ADR Registration Statement or a new registration statement and using its reasonable best efforts to have such amendment or new registration statement declared effective as soon as practicable.

(b) If, at any time prior to the filing of the Final Prospectus pursuant to Rule 424(b), any event occurs as a result of which the Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, the Company will (i) notify promptly the Representative so that any use of the Disclosure Package may cease until it is amended or supplemented; (ii) amend or supplement the Disclosure Package to correct such statement or omission; and (iii) supply any amendment or supplement to the Representative in such quantities as the Representative may reasonably request.

(c) The Company will give the Representative notice of its intention to make any filings pursuant to the Exchange Act from the Execution Time to the Closing Date and any Settlement Date and will furnish the Representative with copies of any such documents a reasonable amount of time prior to such proposed filing.

(d) The Company will comply with the Act and the Exchange Act so as to permit the completion of the distribution of the International Shares as contemplated in this Agreement and in the Disclosure Package and the Final Prospectus. If at any time when a prospectus relating to the International Shares is required (or, but for the exception afforded by

Rule 172, would be required to be delivered) by the applicable law to be delivered in connection with sales of the International Shares, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to amend the Registration Statement or amend or supplement the Disclosure Package or the Final Prospectus so that the Registration Statement, the Disclosure Package or the Final Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made or then prevailing, not misleading, or if it shall be necessary, in the opinion of such counsel, at any such time to amend the Registration Statement or amend or supplement the Disclosure Package or the Final Prospectus in order to comply with the requirements of the Act and the Exchange Act, the Company will promptly notify the Representative and will promptly prepare and file with the Commission, subject to Section 6(a), such amendment or supplement as may be necessary to correct such statement or omission or to comply with such requirements. If at any time an Issuer Free Writing Prospectus conflicts with the information contained in the Registration Statement or if an event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to amend or supplement such Issuer Free Writing Prospectus so that it will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made or then prevailing, not misleading, or if it is necessary, in the opinion of such counsel, to amend or supplement such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission or to comply with such requirements, the Company will, subject to Section 6(a), promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. The Company will use its reasonable best efforts to have any amendment to the Registration Statement or a new registration statement declared effective as soon as practicable in order to avoid any disruption in use of the Final Prospectus.

(e) As soon as reasonably practicable, the Company will make generally available to its security holders and to the Representative an earnings statement or statements of the Company and its subsidiaries which will satisfy the provisions of Section 11(a) of the Act and Rule 158.

(f) The Company will furnish to the Representative and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed, the ADR Registration Statement as originally filed and any Rule 462(b) Registration Statement and of each amendment thereto (including exhibits thereto) and to each other Underwriter a copy of the Registration Statement and the ADR Registration Statement (without exhibits thereto) and, so long as delivery of a prospectus by an Underwriter or dealer may be required by the Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172), as many copies of each Preliminary Prospectus, the Final Prospectus and each Issuer Free Writing Prospectus and any supplement thereto as the Representative may reasonably request. The copies of the Registration Statement, the ADR Registration Statement, each Preliminary Prospectus, the Final Prospectus, each Issuer Free Writing Prospectus and any amendment or supplement thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to ▇▇▇▇▇, except to the extent

permitted by Regulation S-T.

(g) The Company will arrange, if necessary, for the qualification of the International Shares for sale under the laws of such jurisdictions as the Representative may designate and will maintain such qualifications in effect so long as required for the distribution of the International Shares; provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the International Shares, in any jurisdiction where it is not now so subject.

(h) The Company agrees that, unless it has or shall have obtained the prior written consent of the Representative, and each Underwriter, severally and not jointly, agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, it has not made and will not make any offer relating to the International Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the prior written consent of the parties hereto shall be deemed to have been given in respect of the Free Writing Prospectuses included in Schedule IV hereto and any electronic road show. Any such free writing prospectus consented to by the Representative or the Company is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company agrees that (x) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (y) it has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.

(i) The Company will not, without the prior written consent of the Representative, offer, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company or any affiliate of the Company or any Person in privity with the Company or any affiliate of the Company), directly or indirectly, including the filing (or participation in the filing) of a registration statement with the Commission or a similar application with the CNBV in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, any shares of any class of capital stock of the Company, including in the form of Series B Shares or ADSs, or any securities convertible into, or exercisable, or exchangeable for, shares of any class of capital stock of the Company or any securities convertible into, or exercisable, or exchangeable for, any of the foregoing; or publicly announce an intention to effect any such transaction, until the Business Day set forth on Schedule I hereto, provided, however, that the Company may issue and sell Series B Shares pursuant to any employee stock option plan, stock ownership plan or dividend reinvestment plan of the Company in effect at the Execution Time and the Company may issue Series B Shares issuable upon the conversion of securities or the exercise of warrants outstanding at the Execution Time. Notwithstanding the foregoing, if (x) during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or (y) prior to the expiration of

the restricted period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the restricted period, the restrictions imposed in this clause shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event. The Company will provide the Representative and any co-managers and each individual or entity subject to the restricted period pursuant to the lockup letters described in Section 8(t) with prior notice of any such announcement that gives rise to an extension of the restricted period.

(j) The Company will use its best efforts to cause each of the parties identified on Schedule VI to furnish to the Representative, prior to the Execution Time, a letter or letters, substantially in the form of Exhibit A hereto, as applicable (the “Lock-Up Agreements”).

(k) The Company, during the period when the Final Prospectus is required to be delivered (or, but for the exception afforded by Rule 172, would be required to be delivered) under the Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act.

(l) The Company will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Global Shares.

7. Further Agreements of the Selling Shareholder. The Selling Shareholder covenants and agrees with the several Underwriters that:

(a) The Selling Shareholder will not, without the prior written consent of the Representative, offer, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Selling Shareholder or any affiliate of the Selling Shareholder or any Person in privity with the Selling Shareholder or any affiliate of the Selling Shareholder), directly or indirectly, any shares of capital stock of the Company or any securities convertible into, or exercisable, or exchangeable for, shares of any class of capital stock of the Company, including in the form of Series B Shares or ADSs, or any securities convertible into, or exercisable, or exchangeable for, any of the foregoing; or publicly announce an intention to effect any such transaction, until the Business Day set forth on Schedule I hereto, provided, however, the foregoing restrictions shall not apply to (i) transfers of shares of any Series B Shares as a bona fide gift or gifts, (ii) as a distribution to limited partners, members or shareholders of the Selling Shareholder, (iii) transfers of shares of any Series B Shares to any trust for the direct or indirect benefit of the Selling Shareholder or the immediate family of the Selling Shareholder (for purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin) and such transfer does not involve a disposition for value and (iv) transfers of shares of any Series B Shares to the Selling Shareholder’s affiliates or to any investment fund or other entity controlled or managed by the Selling Shareholder; provided, however that in the case of any transfer or distribution pursuant to clause (i) to (iv),

(i) each donee, trustee, distributee, or transferee, as the case may be, shall sign and deliver a Lock-Up Agreement substantially in the form of Exhibit A hereto for the balance of the lockup period, (ii) such transfers are not required to be reported with the Commission on Form 4 in accordance with Section 16 of the Exchange Act, and (iii) the Selling Shareholder does not otherwise voluntarily effect any public filing or report regarding such transfers. Notwithstanding the foregoing, if (x) during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or (y) prior to the expiration of the restricted period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the restricted period, the restrictions imposed in this clause shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, unless the Representative waives, in writing, such extension.

(b) Prior to Closing Date, the Selling Shareholder will deposit or cause to be deposited the Underlying Shares with the Depositary in accordance with the provisions of the Deposit Agreement so that the ADRs evidencing the ADSs to be delivered to the Underwriters at the Closing Date are executed, countersigned and issued by the Depositary against receipt of such Underlying Shares and delivered to the Underwriters at the Closing Date.

(c) The Selling Shareholder will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Global Shares.

(d) The Selling Shareholder agrees to pay the costs and expenses relating to the following matters: (i) the preparation, printing or reproduction and filing with the Commission of the Registration Statement (including financial statements and exhibits thereto), each Preliminary Prospectus, the Final Prospectus and each Issuer Free Writing Prospectus, the ADR Registration Statement, and each amendment or supplement to any of them; (ii) the deposit of the Underlying Shares under the Deposit Agreement, the issuance thereunder of ADSs representing such deposited Underlying Shares, the issuance of ADRs evidencing such ADSs and the fees of the Depositary; (iii) the preparation, printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies of the Registration Statement, each Preliminary Prospectus, the Final Prospectus, the ADR Registration Statement and each Issuer Free Writing Prospectus, and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use in connection with the offering and sale of the International Shares; (iv) the preparation, printing, authentication and delivery of certificates for the International Shares, including any stamp or transfer taxes in connection with the sale of the International Shares; (v) the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with the offering of the International Shares; (vi) the registration of the International Shares under the Act and Exchange Act and the listing of the Series B Shares and ADSs on NASDAQ; (vii) any registration or qualification of the International Shares for offer and sale under the securities or blue sky laws of the several states (including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such registration and qualification, such fees and

expenses not to exceed US$5,000); (viii) any filings required to be made with FINRA (including filing fees and the reasonable and documented fees and expenses of counsel for the Underwriters relating to such filings, such fees and expenses not to exceed US$5,000); (ix) the reasonable and documented transportation and other expenses incurred by or on behalf of Company representatives or by or on behalf of the Underwriters in connection with presentations to prospective purchasers of the International Shares; (x) the reasonable and documented fees and expenses of the Company’s accountants and the reasonable and documented fees and expenses of counsel (including local and special counsel) for the Company and for the Underwriters; and (xi) all other costs and expenses incidental to the performance by the Company of its obligations hereunder.

8. Conditions to the Obligations of the Underwriters. The obligations of the Underwriters to purchase the International Firm Shares and the International Option Shares, as the case may be, shall be subject to the accuracy of the representations and warranties on the part of the Company and the Selling Shareholder contained herein as of the Execution Time, the Closing Date and any Settlement Date pursuant to Section 4 hereof, to the accuracy of the statements of any officer the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and to the following additional conditions:

(a) The Registration Statement, including any Rule 462(b) Registration Statement, and the ADR Registration Statement has become effective, and at the Closing Date or any Settlement Date, no stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement and the ADR Registration Statement or any notice objecting to their use shall have been issued under the Act or proceedings therefor initiated or, to the knowledge of the Company, threatened by the Commission, and any request on the part of the Commission for additional information shall have been complied with to the reasonable satisfaction of counsel to the Underwriters. The Final Prospectus shall have been filed with the Commission in the manner and within the time period required by Rule 424(b) or a post-effective amendment providing such information shall have been filed and declared effective in accordance with the requirements of Rule 430A. Any other material required to be filed by the Company pursuant to Rule 433 under the Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule 433.

(b) The Company shall have requested and caused ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, special U.S. counsel for the Company and the Selling Shareholder, to have furnished to the Representative their opinion and negative assurance letter, dated the Closing Date and addressed to the Representative, in the forms of Exhibit B-1 and B-2 hereto.

(c) The Company shall have requested and caused ▇▇▇▇▇ ▇▇▇▇▇▇▇, S.C., special Mexican counsel for the Company and the Selling Shareholder, to have furnished to the Representative their opinion and negative assurance letter, dated the Closing Date and addressed to the Representative, in the form of Exhibit C-1 and C-2 hereto.

(d) The Depositary shall have requested and caused ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ & Associates LLP, counsel for the Depositary, to have furnished to the Representative their

opinion, dated the Closing Date and addressed to the Representative, in the form of Exhibit D hereto.

(e) The Representative shall have received from ▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, counsel for the Underwriters, such opinion or opinions, dated the Closing Date and addressed to the Representative, with respect to the sale of the International Shares, the Registration Statement, the ADR Registration Statement, the Disclosure Package, the Final Prospectus (together with any supplement thereto) and other related matters as the Representative may reasonably require, and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters.

(f) The Representative shall have received from Raz ▇▇▇▇▇▇, S.C., Mexican counsel for the Underwriters, such opinion or opinions, dated the Closing Date and addressed to the Representative, with respect to the sale of the International Shares, the Disclosure Package, the Final Prospectus (together with any supplement thereto) and other related matters as the Representative may reasonably require, and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters.

(g) The Company shall have furnished to the Representative a certificate of the Company, signed by the chief executive officer and the principal financial or accounting officer of the Company, on behalf of the Company and not in their individual capacity, dated the Closing Date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the ADR Registration Statement, the Disclosure Package, the Final Prospectus and any supplements or amendments thereto, as well as each electronic road show used in connection with the offering of the International Shares, this Agreement and the Mexican Underwriting Agreement and that:

(i)

the representations and warranties of the Company in this Agreement are true and correct on and as of the Closing Date with the same effect as if made on the Closing Date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date;

(ii)

The Registration Statement and the ADR Registration Statement has become effective under the Act and no stop order suspending the effectiveness of the ADR Registration Statement or the Registration Statement or any notice objecting to their use has been issued and no proceedings for that purpose have been instituted or, to the Company’s knowledge, threatened; and

(iii)

since the date of the most recent financial statements included or incorporated by reference in the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto), there has been no event or condition of a type that would, individually or in the aggregate, result in a Material Adverse Effect, except as set forth in

or contemplated in the Disclosure Package and the Final Prospectus (exclusive of any supplement thereto).

(h) The Selling Shareholder shall have furnished to the Representative a certificate of the Selling Shareholder, signed by the Selling Shareholder or appropriate representative or attorney-in-fact on behalf of the Selling Shareholder, dated the Closing Date, to the effect that the representations and warranties of the Selling Shareholder in this Agreement are true and correct on and as of the Closing Date with the same effect as if made on the Closing Date and the Selling Shareholder has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date.

(i) The Company shall have requested and caused Galaz, Yamazaki, ▇▇▇▇ ▇▇▇▇▇▇▇, S.C., member firm of Deloitte Touche Tohmatsu Limited, independent auditors for the Company, to have furnished to the Representative, at the Execution Time and at the Closing Date, letters (which may refer to letters previously delivered to one or more of the Representative), dated respectively as of the Execution Time and as of the Closing Date, in form and substance satisfactory to the Representative, confirming that they are an independent registered public accounting firm within the meaning of the Act and the Exchange Act and covering the matters that are ordinarily covered by “comfort letters” drafted in accordance with Statement of Accounting Standards No. 72.

(j) Subsequent to the Execution Time or, if earlier, the dates as of which information is given in the Registration Statement (exclusive of any amendment thereof) and the Final Prospectus (exclusive of any amendment or supplement thereto), there shall not have been (i) any change or decrease specified in the letter or letters referred to in paragraph (i) of this Section 8 or (ii) any change, or any development involving a prospective change, in or affecting the condition (financial or otherwise), earnings, business or properties of the Company and its subsidiaries taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Disclosure Package and the Final Prospectus (exclusive of any amendment or supplement thereto) the effect of which, in any case referred to in clause (i) or (ii) above, is, in the sole judgment of the Representative, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the International Shares as contemplated by the Registration Statement (exclusive of any amendment thereof), the Disclosure Package and the Final Prospectus (exclusive of any amendment or supplement thereto).

(k) The closing of the purchase of the Mexican Base Shares to be sold by the Selling Shareholder pursuant to the Mexican Underwriting Agreement shall occur concurrently with the closing of the purchase of the International Firm Shares described herein.

(l) The Depositary shall have furnished or caused to be furnished to the Representative certificates satisfactory to the Representative evidencing the deposit with the Custodian of the Underlying Shares in respect of which ADSs are to be issued on the Closing Date, and the execution, issuance, countersignature (if applicable) and delivery of the ADRs evidencing such ADSs pursuant to the Deposit Agreement and such other matters related thereto as the Representative reasonably request.

(m) Prior to the Closing Date, the Company and the Selling Shareholder shall have furnished to the Representative such further information, certificates and documents as the Representative may reasonably request.

(n) FINRA, upon review, if any, of the terms of the public offering of the International Shares, shall not have objected to such offering, such terms or the Underwriters’ participation in the same.

(o) The ADSs and Series B Shares shall have been listed and the ADSs shall have been admitted and authorized for trading on NASDAQ, and satisfactory evidence of such actions shall have been provided to the Representative.

(p) Prior to the Execution Time, the Company shall have furnished to the Representative the Lock-Up Agreements.

(q) The CNBV shall have authorized the public offering of the Mexican Shares. No order or other type of official communication suspending the public offering of the Mexican Shares shall have been issued by the CNBV or a Mexican judicial authority and continue in effect.

(r) All approvals required under the laws of Mexico at the Closing Date, including the approval by the CNBV to conduct a public offering in Mexico of the Mexican Shares shall have been obtained. The Company and the Selling Shareholder will use their commercially reasonable efforts to enforce the terms of each Lock-Up Agreement.

(s) The Series B Shares underlying the International Shares shall have been delivered and credited to the Mexican custodian for the Depositary, through the systems of Indeval as the Representative shall reasonably specify.

(t) There shall not have been any decrease in or withdrawal of the rating of any securities of the Company by any “nationally recognized statistical rating organization” (as defined in Section 3(a)(62) of the Exchange Act) or any notice given of any intended or potential decrease in or withdrawal of any such rating or of a possible change in any such rating that does not indicate the direction of the possible change.

If any of the conditions specified in this Section 8 shall not have been fulfilled when and as provided herein, or if any of the opinions, letters and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Representative and counsel for the Underwriters, this Agreement and all obligations of the Underwriters hereunder may be canceled at, or at any time prior to, the Closing Date by the Representative. Notice of such cancellation shall be given to the Company and the Selling Shareholder in writing or by telephone or facsimile confirmed in writing.

The documents required to be delivered by this Section 8 shall be delivered at the office of ▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, counsel for the Underwriters, at ▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇

▇▇

▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇, on the Closing Date.

9. Reimbursement of Underwriters’ Expenses. If the sale of the International Shares provided for herein is not consummated because any condition to the obligations of the Underwriters set forth in Section 8 hereof is not satisfied, because of any termination pursuant to Section 12 hereof or because of any refusal, inability or failure on the part of the Company or the Selling Shareholder to perform any agreement herein or comply with any provision hereof other than by reason of a default by any of the Underwriters, the Selling Shareholder will reimburse the Underwriters severally through the Representative on demand for all reasonable and documented out-of-pocket expenses (including reasonable and documented fees and disbursements of outside counsel) that shall have been incurred by them in connection with the proposed purchase and sale of the International Shares.

10. Indemnification and Contribution.

(a) The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, as such term is defined in Rule 501(b) under the Act, the directors, officers, employees and agents of each Underwriter and each Person who controls any Underwriter within the meaning of either the Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the International Shares as originally filed or in any amendment thereof, including the Rule 430A Information, or in the ADR Registration Statement as originally filed or in any amendment thereof, or in the Base Prospectus, any Preliminary Prospectus, or any other preliminary prospectus supplement relating to the International Shares, the Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus, or in any amendment thereof or supplement to any of the foregoing or in the English and Spanish presentations, entitled “OMA Roadshow Presentation June 2013” and “OMA Oferta Pública Secundaria Global Junio 2013,” respectively, which were initially made available to prospective investors from June 10, 2013 in connection with the electronic road show (the “Marketing Materials”), or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and agrees to reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with (i) written information furnished to the Company by or on behalf of any Underwriter through the Representative specifically for inclusion therein, it being understood and agreed that the only such information furnished by any Underwriter consists of information described in paragraph (c) below, and (ii) any information relating to the Selling Shareholder furnished in writing

by or on behalf of the Selling Shareholder expressly for use therein, it being understood and agreed that the only such information furnished by or on behalf of the Selling Shareholder consists of the information described as such in paragraph (b) below. This indemnity agreement will be in addition to any liability which the Company may otherwise have.

(b) The Selling Shareholder agrees to indemnify and hold harmless each Underwriter, its affiliates, as such term is defined in Rule 501(b) under the Act, the directors, officers, employees and agents of each Underwriter and each Person who controls any Underwriter within the meaning of either the Act or the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above; provided, however, that the Selling Shareholder shall only be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with the information furnished by or on behalf of the Selling Shareholder specifically for inclusion therein, it being understood and agreed that the only such information furnished by the Selling Shareholder consists of (i) the Selling Shareholder’s legal name, address and the number of Series B Shares owned by the Selling Shareholder, and (ii) the other information (excluding percentages) with respect to the Selling Shareholder which appears in the table (and corresponding footnotes) under the caption “Selling Shareholder” in the Registration Statement, the Disclosure Package, the Final Prospectus or any Issuer Free Writing Prospectus and any amendment or supplement thereto; provided, further, that the liability of the Selling Shareholder pursuant to this paragraph (b) and the contribution by the Selling Shareholder under paragraph (e) below shall not exceed the net proceeds (after deducting underwriting discounts and commissions, but without deducting expenses of the Company or the Selling Shareholder) received by the Selling Shareholder from the sale of the International Shares sold by the Selling Shareholder hereunder.

(c) Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signs the Registration Statement, each Person who controls the Company within the meaning of either the Act or the Exchange Act and the Selling Shareholder to the same extent as the indemnity set forth in paragraph (a) above from the Company to each Underwriter, but only with reference to written information relating to such Underwriter furnished to the Company by or on behalf of such Underwriter through the Representative specifically for inclusion in the documents referred to in the indemnity set forth in paragraph (a) above. This indemnity agreement will be in addition to any liability which any Underwriter may otherwise have. The Company and the Selling Shareholder acknowledge that the following information set forth in the documents referred to in the indemnity set forth in paragraph (a) above under the heading “Plan of Distribution” constitute the only information furnished in writing by or on behalf of the several Underwriters for inclusion in the Registration Statement (or any amendment thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Disclosure Package or the Final Prospectus (or any amendment or supplement to any of the foregoing) or the Marketing Materials: (i) the names of the Underwriters and their respective participation in the sale of the International Shares, (ii) the sentences related to selling concessions and dealer reallowances, (iii) the sentences describing the Intersyndicate Agreement and (iv) the paragraphs related to stabilization, syndicate covering transactions and penalty bids in any Preliminary Prospectus and the Final Prospectus.

(d) Promptly after receipt by an indemnified party under this Section

10 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 10, notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party (i) will not relieve it from liability under paragraph (a), (b) or (c) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the indemnifying party of substantial rights and defenses and (ii) will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided in paragraph (a), (b) or (c) above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party’s choice at the indemnifying party’s expense to represent the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as set forth below); provided, however, that such counsel shall be reasonably satisfactory to the indemnified party. Notwithstanding the indemnifying party’s election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii) the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, (iii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action or (iv) the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. It is understood, however, that with respect to any such indemnified party, the indemnifying party shall, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of only one separate firm of attorneys (in addition to any local counsel) at any time for each such indemnified party, which firm shall be designated in writing by the Representative. An indemnifying party will not, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such claim, action, suit or proceeding and (ii) does not include a statement as to or an admission of fault, culpability or failure to act by or on behalf of any indemnified party.

(e) In the event that the indemnity provided in paragraph (a), (b) or (c) of this Section 10 is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company, the Selling Shareholder and the Underwriters severally agree to contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending the same) (collectively, “Losses”) to which the Company, the Selling Shareholder and one or more of the Underwriters

may be subject in such proportion as is appropriate to reflect the relative benefits received by the Company and the Selling Shareholder on the one hand and by the Underwriters on the other from the offering of the International Shares; provided, however, that in no case shall any Underwriter (except as may be provided in any agreement among the Underwriters relating to the offering of the International Shares) be responsible for any amount in excess of the underwriting discount or commission applicable to the International Shares purchased by such Underwriter hereunder. If the allocation provided by the immediately preceding sentence is unavailable for any reason, the Company, the Selling Shareholder and the Underwriters severally shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company and the Selling Shareholder on the one hand and of the Underwriters on the other in connection with the statements or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company and the Selling Shareholder shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by it and the Selling Shareholder, and benefits received by the Underwriters shall be deemed to be equal to the total underwriting discounts and commissions, in each case as set forth on the cover page of the Final Prospectus. Relative fault shall be determined by reference to, among other things, whether any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information provided by the Company and the Selling Shareholder on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company, the Selling Shareholder and the Underwriters agree that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph (e), no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 10, each Person who controls an Underwriter within the meaning of either the Act or the Exchange Act and each director, officer, employee, affiliate (as such term is defined in Rule 501(b) under the Act) and agent of an Underwriter shall have the same rights to contribution as such Underwriter, and each Person who controls the Company or the Selling Shareholder within the meaning of either the Act or the Exchange Act, each officer or representative of the Company or the Selling Shareholder who shall have signed the Registration Statement and each director of the Company or the Selling Shareholder shall have the same rights to contribution as the Company and the Selling Shareholder, subject in each case to the applicable terms and conditions of this paragraph (e).

11. Default by an Underwriter. If any one or more Underwriters shall fail to purchase and pay for any of the International Shares agreed to be purchased by such Underwriter or Underwriters hereunder and such failure to purchase shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Underwriters shall be obligated severally to take up and pay for (in the respective proportions which the amount of International Shares set forth opposite their names in Schedule II hereto bears to the aggregate amount of International Shares set forth opposite the names of all the remaining Underwriters) the International Shares which the defaulting Underwriter or Underwriters agreed but failed to purchase; provided, however, that in the event that the aggregate amount of

International Shares which the defaulting Underwriter or Underwriters agreed but failed to purchase shall exceed 10% of the aggregate amount of International Shares set forth in Schedule II hereto, the remaining Underwriters shall have the right to purchase all, but shall not be under any obligation to purchase any, of the International Shares, and if such nondefaulting Underwriters do not purchase all the International Shares, this Agreement will terminate without liability to any nondefaulting Underwriter, the Company or the Selling Shareholder. In the event of a default by any Underwriter as set forth in this Section 11, the Closing Date shall be postponed for such period, not exceeding five Business Days, as the Representative shall determine in order that the required changes in the Registration Statement, the ADR Registration Statement and the Final Prospectus or in any other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve any defaulting Underwriter of its liability, if any, to the Company, the Selling Shareholder and any nondefaulting Underwriter for damages occasioned by its default hereunder.

12. Termination. This Agreement shall be subject to termination in the absolute discretion of the Representative, by notice given to the Company and the Selling Shareholder prior to delivery of and payment for the International Shares, if at any time prior to such delivery and payment (i) trading in the Company’s Series B Shares has been suspended by the Mexican Stock Exchange or trading in the Company’s ADSs representing the Series B Shares shall have been suspended by the Commission or the CNBV or NASDAQ or the Mexican Stock Exchange or trading in securities generally on the New York Stock Exchange, NASDAQ or the Mexican Stock Exchange shall have been suspended or limited or minimum prices shall have been established on such exchanges, (ii) a banking moratorium shall have been declared by Mexican or United States federal or New York State authorities, or (iii) there shall have occurred any outbreak or escalation of hostilities, declaration by the United States or Mexico of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Representative, impractical or inadvisable to proceed with the offering or delivery of the International Shares as contemplated by the Registration Statement, any Preliminary Prospectus, the Disclosure Package or the Final Prospectus (exclusive of any amendment or supplement thereto).

13. Representations and Indemnities to Survive. The respective agreements, representations, warranties, indemnities and other statements of the Company, the Selling Shareholder or the respective officers of the Company and the Selling Shareholder, and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company, the Selling Shareholder or any of the officers, directors, employees, agents, affiliates or controlling Persons referred to in Section 10 hereof, and will survive delivery of and payment for the International Shares. The provisions of Sections 9 and 10 hereof shall survive the termination or cancellation of this Agreement.

14. Notices. All communications hereunder will be in writing and effective only on receipt, and, if sent to the Representative, will be mailed, delivered or telefaxed to c/o Merrill Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇, Attention: Syndicate Department (fax no.: (▇▇▇) ▇▇▇-▇▇▇▇), with a copy to ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇,

Attention: ECM Legal (fax no.: (▇▇▇) ▇▇▇-▇▇▇▇), with a copy to ▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇, Esq. (fax no.: (▇▇▇) ▇▇▇-▇▇▇▇) and confirmed to it at ▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, ▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇; if sent to the Company, will be mailed, delivered or telefaxed to Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., Attention: ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ and/or ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ (fax no.: ▇▇▇ (▇▇) ▇ ▇▇▇-▇▇▇▇) and confirmed to it at Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., Ave. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ No. 2225 L.501 (Piso 5), Col. ▇▇▇▇▇ Ote., San ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇.▇., ▇.▇. ▇▇▇▇▇, ▇▇▇▇▇▇, with a copy to ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, Esq. (fax no.: (▇▇▇) ▇▇▇-▇▇▇▇) and confirmed to it at ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇; or, if sent to the Selling Shareholder, will be mailed, delivered or telefaxed to Empresas ICA, S.A.B. de C.V., Attention: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, General Counsel (fax no.: ▇(▇▇) ▇▇▇ ▇▇▇-▇▇▇▇) and confirmed to it at Empresas ICA, S.A.B. de C.V., Boulevard ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ #36, Piso 15, Col. ▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇.▇. ▇▇▇▇▇, ▇▇▇▇▇▇, D.F., with a copy to ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, Esq. (fax no.: (▇▇▇) ▇▇▇-▇▇▇▇) and confirmed to it at ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇.

15. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, affiliates, agents and controlling Persons referred to in Section 10 hereof, and no other Person will have any right or obligation hereunder.

16. No Fiduciary Duty. Each of the Company and the Selling Shareholder hereby acknowledges and agrees that (a) the purchase and sale of the International Shares pursuant to this Agreement is an arm’s-length commercial transaction between the Company and the Selling Shareholder, on the one hand, and the Underwriters and any affiliate through which they may be acting, on the other, (b) the Underwriters are acting as principal and not as an agent or fiduciary of the Company or the Selling Shareholder and (c) the engagement of the Underwriters by the Company in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity. Furthermore, each of the Company and the Selling Shareholder agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective of whether any of the Underwriters has advised or is currently advising the Company or the Selling Shareholder on related or other matters). Each of the Company and the Selling Shareholder agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company or the Selling Shareholder, in connection with such transaction or the process leading thereto.

17. Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) by and among the Company, the Selling Shareholder and the Underwriters, or any of them, with respect to the subject matter hereof.

18. Applicable Law. THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED WITHIN THE STATE OF NEW YORK.

19. Jurisdiction. Each of the parties hereto hereby agrees that any suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) shall be instituted in any New York Court. Each of the parties hereto irrevocably submits to the jurisdiction of the New York Courts in any Related Proceeding and agrees not to commence any Related Proceeding except in the New York Courts. Each of the parties hereto irrevocably and unconditionally waives any right to the jurisdiction of any other courts by reason of present or future domicile or otherwise, any objection to the laying of venue of any Related Proceeding in the New York Courts and irrevocably and unconditionally waive and agree not to plead or claim in any New York Court that any Related Proceeding brought in any New York Court has been brought in an inconvenient forum. A final judgment in any Related Proceeding (a “Related Judgment”) from a New York Court shall be conclusive and may be enforced in any other jurisdiction by suit on the judgment or in any other manner provided by law, and the parties hereto submit to the jurisdiction of the courts of any such other jurisdiction for such purpose. The Company and the Selling Shareholder have appointed CT Corporation System, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇, as their authorized agent (the “Authorized Agent”) upon whom process may be served in any suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated herein which may be instituted in any New York Court, by any Underwriter, the directors, officers, employees and agents of any Underwriter, or by any Person who controls any Underwriter, and expressly accepts the jurisdiction of any such court in respect of any such suit, action or proceeding. The Company and the Selling Shareholder hereby represent and warrant that the Authorized Agent has accepted such appointment and has agreed to act as said agent for service of process, and the Company and the Selling Shareholder agree to take any and all action, including the filing of any and all documents that may be necessary to continue such appointment in full force and effect as aforesaid. Service of process upon the Authorized Agent shall be deemed, in every respect, effective service of process upon the Company or the Selling Shareholder.

The provisions of this Section 19 shall survive any termination of this Agreement, in whole or in part.

20. Currency; Additional Amounts.

(a) Each reference in this Agreement to dollars, U.S. dollars or US$ (the “Relevant Currency”) is of the essence. To the fullest extent permitted by law, the obligations of the Company and the Selling Shareholder in respect of any amount due under this Agreement will, notwithstanding any payment in any other currency (whether pursuant to a judgment or otherwise), be discharged only to the extent of the amount in the Relevant Currency that the party entitled to receive such payment may, in accordance with its normal procedures, purchase with the sum paid in such other currency (after any premium and costs of exchange) on the Business Day immediately following the day on which such party receives such payment. If the amount in the Relevant Currency that may be so purchased for any reason falls short of the amount originally due, the Company or the Selling Shareholder will pay such additional amounts, in the Relevant Currency, as may be necessary to compensate for the shortfall. Any obligation of the Company and the Selling Shareholder not discharged by such payment will, to the fullest extent permitted by applicable law, be due as a separate and independent obligation

and, until discharged as provided herein, will continue in full force and effect.

(b) Each payment of fees or other amounts due to the Underwriters under this Agreement shall, except as required by law, be made without withholding or deduction for or on account of any taxes imposed by Mexico or any political subdivision or taxing authority thereof or therein. If any taxes are required to be withheld or deducted from any such payment, the Selling Shareholder shall pay such additional amounts as may be necessary to ensure that the net amount actually received by the Underwriters after such withholding or deduction is equal to the amount that the Underwriter would have received had no such withholding or deduction been required, provided, however, that no such additional amounts shall be payable in respect of (i) any taxes imposed on the net income of an Underwriter and franchise taxes imposed on an Underwriter by the jurisdiction under the laws of which the Underwriter is organized or has its principal place of business, or (ii) any taxes imposed on an Underwriter by reason of any connection between the Underwriter and the taxing jurisdiction other than entering into this Agreement and receiving payments hereunder, including such Underwriter being a resident or having a permanent establishment for tax purposes in such taxing jurisdiction.

21. Waiver of Immunity. With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the New York Courts, and with respect to any Related Judgment, each party waives any such immunity in the New York Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.

22. Waiver of Jury Trial. Each of the Company and the Selling Shareholder hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

23. Counterparts. This Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement.

24. Headings. The section headings used herein are for convenience only and shall not affect the construction hereof.

25. Definitions. The terms that follow, when used in this Agreement, shall have the meanings indicated.

“Act” shall mean the United States Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.

“ADR Registration Statement” shall mean the registration statement referred to in paragraph 1(nn) above, including exhibits thereto and the prospectuses included therein, each as amended at the time such part of the registration statement became effective.

“Base Prospectus” shall mean the base prospectus referred to in paragraph 1(a) above contained in the Registration Statement at the Execution Time, including all documents incorporated by reference therein.

“Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated by law to close in New York City or Mexico City, Mexico.

“Commission” shall mean the United States Securities and Exchange Commission.

“Disclosure Package” shall mean (i) the Base Prospectus, (ii) the Preliminary Prospectus used most recently prior to the Execution Time, (iii) the Issuer Free Writing Prospectuses, if any, issued at or prior to the Execution Time and identified in Schedule IV hereto, and (iv) any other Free Writing Prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of the Disclosure Package, including all documents incorporated by reference in any of (i) through (iv) above.

“▇▇▇▇▇” shall mean the Commission's Electronic Data Gathering, Analysis and Retrieval System or any successor system.

“Effective Date” shall mean each date and time that the Registration Statement and the ADR Registration Statement and any post-effective amendment or amendments thereto became or becomes effective, as the case may be.

“Exchange Act” shall mean the United States Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.

“Execution Time” shall mean the date and time that this Agreement is executed and delivered by the parties hereto.

“Final Prospectus” shall mean the prospectus supplement relating to the International Shares that was first filed pursuant to Rule 424(b) in the form first furnished to the Underwriters after the Execution Time, including all documents incorporated by reference therein, together with the Base Prospectus.

“Free Writing Prospectus” shall mean a free writing prospectus, as defined in Rule 405.

“Issuer Free Writing Prospectus” shall mean any “issuer free writing prospectus,” as defined in Rule 433, relating to the International Shares that (i) is required to be filed with the Commission by the Company, (ii) is a “road show” that is a

“written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the International Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form required to be retained in the Company’s records pursuant to Rule 433(g).

“Material Adverse Effect” shall mean, with respect to any Person, a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of such Person and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business.

“New York Courts” shall mean the United States federal or state courts located in the Borough of Manhattan in the City and State of New York.

“Preliminary Prospectus” shall mean any preliminary prospectus supplement to the Base Prospectus referred to in paragraph 1(a) above which is used prior to the Effective Time, including all documents incorporated by reference therein, together with the Base Prospectus.

“Registration Statement” shall mean the registration statement referred to in paragraph 1(a) above, including exhibits and financial statements and any prospectus supplement relating to the International Shares that is filed with the Commission pursuant to Rule 424(b) and deemed part of such registration statement pursuant to Rule 430A, as amended, on each Effective Date and, in the event any post-effective amendment thereto or any Rule 462(b) Registration Statement becomes effective prior to the Closing Date, shall also mean such registration statement as so amended or such Rule 462(b) Registration Statement, as the case may be.

“Rule 158,” “Rule 164,” “Rule 172,” “Rule 405,” “Rule 415,” “Rule 424,” “Rule 430A,” “Rule 433,” “Rule 436” and “Rule 462” refer to such rules under the Act.

“Rule 430A Information” shall mean the information included in the Final Prospectus or any amendment or supplement thereto that was omitted from the Registration Statement at the time it became effective but that is deemed to be a part of the Registration Statement at the time it became effective pursuant to Rule 430A.

“Rule 462(b) Registration Statement” shall mean a registration statement filed by the Company pursuant to Rule 462(b) for the purpose of registering any of the International Shares under the Act, including the documents and other information incorporated by reference therein and the Rule 430A Information.

“subsidiary” shall mean each direct and indirect subsidiary of the Company, except as the context otherwise requires.

“significant subsidiary” shall have the meaning set forth in Section 1(ll).

“Underlying Shares” shall mean the Series B Shares that will be represented by the ADSs.

If the foregoing is in accordance with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon this Agreement and your acceptance shall represent a binding agreement among the Company, the Selling Shareholder and the several Underwriters.

Very truly yours,

GRUPO AEROPORTUARIO DEL CENTRO NORTE, S.A.B. DE C.V.

By: /s/ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇

Name: ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇

Title: Chief Financial Officer

[Signature Page to the Underwriting Agreement]

AEROINVEST, S.A. DE C.V.

By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Kawage

Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Kawage

Title: Attorney-in-fact

[Signature Page to the Underwriting Agreement]

The foregoing Agreement is

hereby confirmed and accepted

as of the date first written above.

For themselves and as Representative of the other several Underwriters, if any, listed on Schedule II hereto:

▇▇▇▇▇▇▇ LYNCH, PIERCE, ▇▇▇▇▇▇ & ▇▇▇▇▇

INCORPORATED

By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Title: Managing Director

[Signature Page to the Underwriting Agreement]

For themselves only:

BANCO BILBAO VIZCAYA ARGENTARIA, S.A.

By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Title: Managing Director, Head of Global ECM

By: /s/ ▇▇▇▇▇▇▇ Pertejo de ▇▇▇▇

Name: ▇▇▇▇▇▇▇ Pertejo de ▇▇▇▇

Title: Associate

SANTANDER INVESTMENT SECURITIES INC.

By: /s/ ▇▇▇▇ ▇▇▇▇▇▇▇

Name: ▇▇▇▇ ▇▇▇▇▇▇▇

Title: Executive Director, Head of U.S. Corporates

By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇

Name: ▇▇▇▇▇▇ ▇▇▇▇▇

Title: Managing Director

BARCLAYS CAPITAL INC.

By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇

Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇

Title: Managing Director

▇▇▇▇▇▇ ▇▇▇▇▇▇▇ & CO. LLC

By: /s/ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇

Name: ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇

Title: Vice President

[Signature Page to the Underwriting Agreement]

SCHEDULE I

Underwriting Agreement dated July 9, 2013

Representative: ▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated

Title, Purchase Price and Description of International Shares:

Title: Series B Shares, without par value (or in the form of American Depositary Shares)

Number of International Firm Shares to be sold by the Selling Shareholder: 36,000,000

Number of International Option Shares to be sold by the Selling Shareholder: 5,400,000

Price per International Share to Public (include accrued dividends, if any): Ps. 40.00 per Series B Share or $24.755 per ADS

Price per International Share to the Underwriters – total: Ps. 38.90 per Series B Share or $24.0742 per ADS

Other provisions:

Closing Date, Time and Location: July 12, 2013 at 10:00 a.m. at the offices of ▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, ▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

Type of Offering: Non-Delayed

Date referred to in Section 6(i) after which the Company may offer or sell Series B Shares or other shares of capital stock of the Company without the consent of the Representative: October 7, 2013

Date referred to in Section 7(a) after which the Selling Shareholder may offer or sell Series B Shares or other shares of capital stock of the Company without the consent of the Representative: July 9, 2014

Modification of items to be covered by the letter from Galaz, Yamazaki, ▇▇▇▇ ▇▇▇▇▇▇▇, S.C., a member firm of Deloitte Touche Tohmatsu Limited, delivered pursuant to Section 8(i) at the Execution Time: None

SCHEDULE II

Underwriters	Number of International Firm Shares to be Purchased	Number of International Option Shares to be Purchased
▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated	15,681,600	2,352,240
Banco Bilbao Vizcaya Argentaria, S.A. (1)	7,844,400	1,176,660
Santander Investment Securities Inc.	7,844,400	1,176,660
Barclays Capital Inc	2,314,800	347,220
▇▇▇▇▇▇ ▇▇▇▇▇▇▇ & Co. LLC	2,314,800	347,220
	_______________	_______________
Total	36,000,000	5,400,000

(1) Banco Bilbao Vizcaya Argentaria, S.A., one of the Underwriters, is only participating in the offering of shares outside of the United States under Regulation S of the Securities Act. Banco Bilbao Vizcaya Argentaria, S.A. is not a broker-dealer registered with the Commission and will not be offering or selling securities in the United States or to U.S. nationals or residents.

SCHEDULE III

Selling Shareholder	Number of International Firm Shares to be Sold	Number of International Option Shares to be Sold
Aeroinvest, S.A. de C.V.	36,000,000	5,400,000

SCHEDULE IV

Schedule of Free Writing Prospectuses included in the Disclosure Package:

None.

SCHEDULE V

“Significant Subsidiaries” (as such term is defined under Rule 1-02(w) subsections 1 or 2 of Regulation S-X under the Act) of the Company:

Aeropuerto de Monterrey, S.A. de C.V.

SCHEDULE VI

Directors, Officers and Shareholders Subject to Lock-Up:

▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇

▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇

▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇

▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇

▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇

▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Kawage

▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

▇▇▇▇▇▇ Grediaga Kuri

EXHIBIT A

[Form of Lock-Up Agreement]

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇

Incorporated

As Representative of the Underwriters

Ladies and Gentlemen:

This letter is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”), between Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., a sociedad anónima bursátil de capital variable organized under the laws of the United Mexican States (the “Company”), Aeroinvest, S.A. de C.V., a sociedad anónima de capital variable organized under the laws of the United Mexican States, and you as representative (the “Representative”) of a group of Underwriters named therein, relating to an underwritten public offering of Series B shares of common stock, without par value, of the Company (the “Series B Shares”), directly or in the form of American Depositary Shares (the “ADSs”).

In order to induce you and the other Underwriters to enter into the Underwriting Agreement, the undersigned will not, during the period commencing on the date hereof and ending 90 days after the date of the Underwriting Agreement (the “Lock-up Period”), without the prior written consent of ▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, consent, offer, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any affiliate of the undersigned or any person in privity with the undersigned or any affiliate of the undersigned), directly or indirectly, including the filing (or participation in the filing) of a registration statement with the United States Securities and Exchange Commission (the “Commission”) or a similar application with the Comisión Nacional Bancaria y de Valores to authorize a public offering within Mexico, in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, any shares of any class of capital stock of the Company or any securities convertible into, or exercisable, or exchangeable for, shares of any class of capital stock of the Company, including in the form of Series B Shares or ADSs, or any securities convertible into, or exercisable, or exchangeable for, any of the foregoing (collectively, the “Lock-Up Securities”); or publicly announce an intention to effect any such transaction, provided, however, the foregoing restrictions shall not apply to (i) transfers of shares of any Lock-Up Securities as a bona fide gift or gifts, (ii) as a distribution to limited partners, members or shareholders of the undersigned, (iii) transfers of shares of any Lock-Up Securities to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this letter, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin) and such transfer does not involve a disposition for value and (iv) transfers of shares of any Lock-Up Securities to

the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned; provided, however that in the case of any transfer or distribution pursuant to clause (i) to (iv), (A) each donee, trustee, distributee, or transferee, as the case may be, shall sign and deliver a lock-up letter substantially in the form of this letter for the balance of the Lock-up Period (B) any such transfer shall not involve a disposition for value, (C) such transfers are not required to be reported with the Commission on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and (D) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers.

If (i) the Company issues an earnings release or material news, or a material event relating to the Company occurs, during the last 17 days of the Lock-up Period, or (ii) prior to the expiration of the Lock-up Period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the Lock-up Period, the restrictions imposed by this agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, unless the Representative waives, in writing, such extension. The undersigned hereby acknowledges that the Company has agreed in the Underwriting Agreement to provide written notice of any event that would result in an extension of the Lock-up Period and agrees that any such notice properly delivered will be deemed to have given to, and received by, the undersigned.

If for any reason the Underwriting Agreement shall be terminated prior to the Closing Date (as defined in the Underwriting Agreement), the agreement set forth above shall likewise be terminated.

Yours very truly,

__________________________________

Name: ______________________________

Title: ______________________________

Address: ____________________________

EXHIBIT B-1

[Form of Opinion Letter of ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, special U.S. Counsel to the Company and the Selling Shareholder]

July 12, 2013

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated

▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

as Representative of the several Underwriters

Ladies and Gentlemen:

We have acted as special United States counsel to Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (the “Company”), a sociedad anonima bursatil de capital variable, and Aeroinvest, S.A. de C.V. (the “Selling Shareholder”), a sociedad anonima de capital variable, each organized under the laws of the United Mexican States (“Mexico”), in connection with the Selling Shareholder’s offering pursuant to a registration statement on Form F-3 (No. 333-188624) of 60,000,000 of the Company’s Series B shares, with no par value (“Series B Shares”), directly or in the form of American Depositary Shares (“ADSs”), each representing eight Series B Shares (collectively, the “Securities”). The ADSs are evidenced by American Depositary Receipts (“ADRs”) issued pursuant to the deposit agreement (the “Deposit Agreement”), effective as of December 27, 2012, among the Company, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”) and all registered holders from time to time of any ADRs issued thereunder. Such registration statement, as amended as of its most recent effective date (July [9], 2013), insofar as it relates to the Securities (as determined for purposes of Rule 430B(f)(2) under the Securities Act of 1933, as amended (the “Securities Act”)), but excluding the documents incorporated by reference therein, is herein called the “Registration Statement;” the related prospectus dated May 15, 2013, included in the Registration Statement filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act, but excluding the documents incorporated by reference therein, is herein called the “Base Prospectus;” the preliminary prospectus supplement dated July 8, 2013, as filed with the Commission pursuant to Rule 424(b) under the Securities Act, but excluding the documents incorporated by reference therein, is herein called the “Preliminary Prospectus Supplement”; and the related prospectus supplement dated July [9], 2013, as filed with the Commission pursuant to Rule 424(b) under the Securities Act, but excluding the documents incorporated by reference therein, is herein called the “Final Prospectus Supplement.” The Base Prospectus and the Preliminary Prospectus Supplement together are herein called the “Pricing Prospectus,” and the Base Prospectus and the Final Prospectus Supplement together are herein called the “Final Prospectus.”

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, p. 2

This opinion letter is furnished to you pursuant to Section 8(b) of the underwriting agreement dated July 9, 2013 (the “Underwriting Agreement”) between the Company and the several underwriters named in Schedule II thereto (the “Underwriters”).

In arriving at the opinions expressed below, we have reviewed the following documents:

(a) an executed copy of the Underwriting Agreement;

(b) the Registration Statement and the documents incorporated by reference therein;

(d)

the Final Prospectus and the documents incorporated by reference therein;

(e)

an executed copy of the Deposit Agreement;

(f)

the form of the ADRs attached to the Deposit Agreement; and

(g) the documents delivered to you by the Company at the closing pursuant to the Underwriting Agreement.

In addition, we have made such investigations of law as we have deemed appropriate as a basis for the opinions expressed below.

In rendering the opinions expressed below, we have assumed the authenticity of all documents submitted to us as originals and the conformity to the originals of all documents submitted to us as copies. In addition, we have assumed and have not verified (i) the accuracy as to factual matters of each document we have reviewed (including, without limitation, the accuracy of the representations and warranties of the Company in the Underwriting Agreement) and (ii) that the ADRs in global form conform to the form thereof that we have reviewed.

Based on the foregoing, and subject to the further assumptions and qualifications set forth below, it is our opinion that:

1. The Underwriting Agreement has been duly executed and delivered by the Company and the Selling Shareholder under the laws of the State of New York.

2. The Deposit Agreement has been duly executed and delivered by the Company under the laws of the State of New York and constitutes a valid, binding and enforceable agreement of the Company.

3. Upon due issuance by the Depositary of the ADRs (including any master ADR issued in connection therewith) evidencing ADSs against the deposit of the Series B Shares in respect thereof in accordance with the provisions of the Deposit Agreement, such ADRs will be duly issued and the persons in whose names the ADRs are registered will be entitled to the rights specified therein and in the Deposit Agreement.

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, p. 3

4. The sale of the Securities to the Underwriters pursuant to the Underwriting Agreement and the deposit of the Series B Shares with the Depositary against the issuance of ADRs evidencing the ADSs do not, and the performance by each of the Company and the Selling Shareholder of its obligations in the Underwriting Agreement and the Deposit Agreement will not, (a) require any consent, approval, authorization, registration or qualification of or with any governmental authority of the United States or the State of New York that in our experience normally would be applicable to general business entities with respect to such issuance, sale or performance, except such as have been obtained or effected under the Securities Act and the Securities Exchange Act of 1934, as amended (but we express no opinion relating to any state securities or Blue Sky laws), or (b) result in a violation of any United States federal or New York State law that in our experience normally would be applicable to general business entities with respect to such issuance, sale or performance (but we express no opinion relating to the United States federal securities laws or to any state securities or Blue Sky laws).

5. No registration of the Company under the U.S. Investment Company Act of 1940, as amended, is required for the offer and sale of the Securities by the Selling Shareholder in the manner contemplated by the Underwriting Agreement and the Final Prospectus.

6. The statements under the headings “Description of the American Depositary Shares” in the Final Prospectus, insofar as such statements purport to summarize certain provisions of the Deposit Agreement, provide a fair summary of such provisions; and the statements set forth in the Final Prospectus under the heading “Taxation”, insofar as such statements purport to summarize certain federal income tax laws of the United States, constitute a fair summary of the principal U.S. federal income tax consequences of an investment in the Securities by a U.S. Holder (as defined in the Final Prospectus).

7. Under the law of the State of New York relating to submission to jurisdiction, each of the Company and the Selling Shareholder has, pursuant to Section 19 of the Underwriting Agreement, and the Company has pursuant to Section 19 of the Deposit Agreement, (i) validly and irrevocably submitted to the personal jurisdiction of any New York State or United States federal court located in the Borough of Manhattan, the City of New York, in any action arising out of or based upon the Underwriting Agreement or the Deposit Agreement, as the case may be, (ii) to the fullest extent permitted by law, validly and irrevocably waived any objection to the venue of a proceeding in any such court and (iii) validly appointed CT Corporation System, located at ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇, as its initial authorized agent for the purpose described in Section 19 of the Underwriting Agreement and Section 19 of the Deposit Agreement; and service of process effected in the manner set forth in Section 19 of the Underwriting Agreement will be effective to confer valid personal jurisdiction over the Company or the Selling Shareholder in any such action, and service of process effected in the manner set forth in Section 19 of the Deposit Agreement will be effective to confer valid personal jurisdiction over the Company in any such action.

We confirm to you that (a) based solely upon email confirmation of receipt of the filing and Rule 462(e) under the Securities Act, the Registration Statement is effective under the Securities Act and (b) based solely upon our review of the website of the Commission, no stop

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, p. 4

order with respect thereto has been issued by the Commission, and, to the best of our knowledge, no proceeding for that purpose has been instituted or threatened, by the Commission. To the best of our knowledge, no order directed to any document incorporated by reference in the Registration Statement or the Final Prospectus has been issued by the Commission and remains in effect, and no proceeding for that purpose has been instituted or threatened by the Commission.

Insofar as the foregoing opinions relate to the validity, binding effect or enforceability of any agreement or obligation of the Company or the Selling Shareholder, (a) we have assumed that the Company, the Selling Shareholder and each other party to such agreement or obligation has satisfied those legal requirements that are applicable to it to the extent necessary to make such agreement or obligation enforceable against it (except that no such assumption is made as to the Company or the Selling Shareholder regarding matters of the federal law of the United States of America or the law of the State of New York that in our experience normally would be applicable to general business entities with respect to such agreement or obligation), (b) such opinions are subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and to general principles of equity and (c) such opinions are subject to the effect of judicial application of foreign laws or foreign governmental actions affecting creditors’ rights. We express no opinion with respect to Section 16 of the Deposit Agreement providing for indemnification.

We note that the designation in Section 19 of the Underwriting Agreement of the United States federal courts in New York City as the venue for actions or proceedings arising out of or based upon the Underwriting Agreement is (notwithstanding the waiver in Section 19 of the Underwriting Agreement) subject to the power of such courts to transfer actions pursuant to 28 U.S.C. § 1404(a) or to dismiss such actions or proceedings on the grounds that such a federal court is an inconvenient forum for such an action or proceeding.

With respect to Section 19 of the Underwriting Agreement, we express no opinion as to the subject matter jurisdiction of any United States federal court to adjudicate any action where jurisdiction based on diversity of citizenship under 28 U.S.C. § 1332 does not exist.

We express no opinion as to the enforceability of Section 20 of the Underwriting Agreement relating to currency indemnity.

We note that the enforceability of the waiver of immunities by each of the Company and the Selling Shareholder set forth in Section 21 of the Underwriting Agreement is subject to the limitations imposed by the Foreign Sovereign Immunities Act of 1976.

The foregoing opinions are limited to the federal law of the United States of America and the law of the State of New York.

We are furnishing this opinion letter to you, as Representative of the Underwriters, solely for the benefit of the Underwriters in their capacity as such in connection with the offering of the Securities. This opinion letter is not to be relied on by or furnished to any other person or used, circulated, quoted or otherwise referred to for any other purpose. We

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, p. 5

assume no obligation to advise you, or to make any investigations, as to any legal developments or factual matters arising subsequent to the date hereof that might affect the opinions expressed herein.

Very truly yours,

▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP

By____________________________________

▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇, a Partner

EXHIBIT B-2

[Form of 10b-5 Letter of

▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, special U.S. Counsel to the Company and the Selling Shareholder]

July 12, 2013

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated

▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

as Representative of the several Underwriters

Ladies and Gentlemen:

This letter is furnished to you pursuant to Section 8(b) of the underwriting agreement dated July 9, 2013 (the “Underwriting Agreement”) between the Company and the several underwriters named in Schedule II thereto (the “Underwriters”).

Because the primary purpose of our professional engagement was not to establish or confirm factual matters or financial, accounting or statistical information, and because many determinations involved in the preparation of the Registration Statement, the Pricing Prospectus, the Final Prospectus and the documents incorporated by reference in each of them are of a wholly or partially non-legal character or relate to legal matters outside the scope of our opinion letter to you of even date herewith, we are not passing upon and do not assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Registration Statement, the Pricing Prospectus, the Final Prospectus or the documents incorporated by reference in each of them (except to the extent set forth in numbered paragraph 6 of our opinion letter to you of even date herewith) and we make no representation that we have independently verified the accuracy, completeness or fairness of such statements (except as aforesaid). We also are not passing upon and do not assume any responsibility for ascertaining whether or when any of the Pricing Prospectus, the Final Prospectus or the documents incorporated by reference in each of them was conveyed to any person for purposes of Rule 159 under the Securities Act.

However, in the course of our acting as special United States counsel to the Company and the Selling Shareholder in connection with the Company’s preparation of the Registration Statement, the Pricing Prospectus and the Final Prospectus, we participated in conferences and telephone conversations with representatives of the Company, representatives of the Selling Shareholder, representatives of the independent public accountants for the Company, representatives of Mexican counsel to the Company and the Selling Shareholder, your representatives and representatives of your Mexican and United States counsel, during which conferences and conversations the contents of the Registration Statement, the Pricing Prospectus, the Final Prospectus and portions of certain of the documents incorporated by reference in each of them and related matters were discussed, and we reviewed certain corporate records and documents furnished to us by the Company and the Selling Shareholder.

Based on our participation in such conferences and conversations and our review of such records and documents as described above, our understanding of the U.S. federal securities laws and the experience we have gained in our practice thereunder, we advise you that:

(a) The Registration Statement (except the financial statements and schedules and other financial data included therein, as to which we express no view), at the time it became effective, and the Final Prospectus (except as aforesaid), as of the date thereof, appeared on their face to be appropriately responsive in all material respects to the requirements of the Securities Act and the rules and regulations thereunder.

(b) The documents incorporated by reference in the Registration Statement and the Final Prospectus (except the financial statements and schedules and other financial data and management’s report on the effectiveness of internal control over financial reporting included therein, as to which we express no view), as of the respective dates of their filing with the

Commission, appeared on their face to be appropriately responsive in all material respects to the requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

(c) No information has come to our attention that causes us to believe that the Registration Statement, including the documents incorporated by reference therein (except the financial statements and schedules and other financial data and management’s report on the effectiveness of internal control over financial reporting included therein, as to which we express no view), at the time it became effective, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

(d) No information has come to our attention that causes us to believe that the Pricing Prospectus, including the documents incorporated by reference therein, considered together with the amount and the price to the public of the Securities on the front cover of the Final Prospectus (except in each case the financial statements and schedules and other financial data and management’s report on the effectiveness of internal control over financial reporting included in the Pricing Prospectus, as to which we express no view) at 8:55 a.m. Eastern time on July [9], 2013, contained an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(e) No information has come to our attention that causes us to believe that the Final Prospectus, including the documents incorporated by reference therein (except the financial statements and schedules and other financial data and management’s report on the effectiveness of internal control over financial reporting included therein, as to which we express no view), as of the date thereof or hereof, contained or contains an untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

We are furnishing this letter to you, as Representative of the Underwriters, solely for the benefit of the Underwriters in their capacity as such in connection with the offering of the Securities. This letter is not to be relied on by or furnished to any other person or used, circulated, quoted or otherwise referred to for any other purpose. We assume no obligation to advise you, or to make any investigations, as to any legal developments or factual matters arising subsequent to the date hereof that might affect the views expressed herein.

Very truly yours,

▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP

By____________________________________

▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇, a Partner

EXHIBIT C-1

[Form of Opinion Letter of

▇▇▇▇▇ ▇▇▇▇▇▇▇, S.C., special Mexican counsel to the Company and the Selling Shareholder]

July 12, 2013

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated

Bank of America Tower

▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇,

as Representative of the several

Underwriters

▇▇▇▇▇▇▇ ▇▇▇▇▇ México, S.A. de C.V.,

Casa de Bolsa

▇▇▇▇▇ ▇▇ ▇▇ ▇▇▇▇▇▇▇ ▇▇▇

▇▇▇▇ ▇▇

Col. ▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇▇▇

▇▇▇▇▇ ▇▇▇▇▇▇, Distrito Federal

Casa de Bolsa BBVA Bancomer, S.A. de C.V.,

Grupo Financiero BBVA Bancomer

▇▇▇▇▇▇ Urales No. 620

Segundo Piso

Col. ▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇▇▇

▇▇▇▇▇ ▇▇▇▇▇▇, Distrito Federal

Casa de Bolsa Santander, S.A. de C.V.,

Grupo Financiero Santander México

Prolongación Paseo de la Reforma No. 500

Módulo 104

Col. ▇▇▇▇▇ ▇▇ ▇▇▇▇▇ ▇▇

▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Ladies and Gentlemen:

We have acted as special Mexican counsel to Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (the “Company”) and to Aeroinvest, S.A. de C.V., as selling shareholder (the “Selling Shareholder”), in connection with (i) the underwriting agreement dated July 9, 2013 (the “Underwriting Agreement”), entered into among the Company, the Selling Shareholder, and ▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, as representative of the Underwriters named in Schedule II thereto (the “Representative”), and (ii) the Mexican underwriting agreement (contrato de colocación) dated July 9, 2013 (the “Mexican Underwriting Agreement”), entered into among the Company, the Selling Shareholder, and ▇▇▇▇▇▇▇ ▇▇▇▇▇ México, S.A. de C.V., Casa de Bolsa, Casa de Bolsa BBVA Bancomer, S.A. de C.V., Grupo Financiero BBVA Bancomer, and Casa de Bolsa Santander, S.A. de C.V., Grupo Financiero Santander México, as intermediarios colocadores líderes (together, the “Mexican Underwriters”). Capitalized terms used herein and not otherwise defined, are used herein as defined in the Underwriting Agreement. This opinion is furnished to you, at your request, pursuant to Section 8(c) of the Underwriting Agreement and Clause Eleventh, Section ___, of the Mexican Underwriting Agreement.

In rendering the opinion expressed below, we have examined copies of the following documents:

(a)	the Underwriting Agreement;

(b)	the Mexican Underwriting Agreement;

(c)	the Deposit Agreement;

(d)	the estatutos sociales of the Company;

(e)	the estatutos sociales of the Selling Shareholder;

(f)	minutes of the meeting of the board of directors of the Company, held on May 9, 2013;

(g)	powers-of-attorney granted to officers of each of the Company and the Selling Shareholder executing each of the Underwriting Agreement and the Mexican Underwriting Agreement; and

(h)	such other documents, agreements and instruments, and such Mexican laws, rules and regulations, as we have deemed relevant or appropriate in connection with the giving of this opinion.

We have assumed, without any independent investigation or verification of any kind, (i) the power and authority of the Representative, the Mexican Underwriters and the Depositary, under all applicable laws, rules, regulations and their respective constitutive or similar documents, to enter into and perform their respective obligations under each of the Underwriting Agreement, the Mexican Underwriting Agreement and the Deposit Agreement, as the case may be, and the due authorization by all parties thereto (other than the Company and the Selling Shareholder) and due execution by all parties thereto (other than the Company and the Selling Shareholder) of each of the Underwriting Agreement, the Mexican Underwriting Agreement and the Deposit Agreement, (ii) that all approvals (other than approvals required under the laws of Mexico, which are addressed in this opinion) necessary for the validity and enforceability of each of the Underwriting Agreement, the Mexican Underwriting Agreement and the Deposit Agreement, have been obtained and are in full force and effect, (iii) the validity, binding effect and enforceability of each of the Underwriting Agreement and the Deposit Agreement under the laws of the State of New York, United States of America, and of the United States of America, (iv) the genuineness of all signatures and the authenticity of all opinions, documents and papers submitted to us, and (v) that copies of all opinions, documents and papers submitted to us are complete and conform to the originals thereof.

As to questions of fact material to the opinion hereinafter expressed, we have, when relevant facts were not independently established by us, relied upon originals or copies, certified or otherwise identified to our satisfaction, of all such corporate records of the Company and the Selling Shareholder, and such other instruments or certificates of public officials, officers and representatives of the Company, the Selling Shareholder and such other persons, as we have deemed necessary or appropriate for the opinion expressed below.

We have made no independent investigation of the laws of the United States of America or any State thereof, as a basis for the opinion stated herein, and we have assumed that there is nothing in any such laws that affects our opinion.

Based upon the foregoing and subject to the qualifications set forth below, we are of the opinion that:

1. The Company is a sociedad anónima bursátil de capital variable, duly organized and validly existing under the laws of Mexico.

2. The Selling Shareholder is a sociedad anónima de capital variable, duly organized and validly existing under the laws of Mexico.

3. The execution and performance by each of the Company and the Selling Shareholder of each of the Underwriting Agreement and the Mexican Underwriting Agreement are within each of the Company’s and the Selling Shareholder’s corporate power, have been duly authorized by all necessary corporate action and do not contravene any Mexican Federal law, rule or regulation, or the estatutos sociales of the Company or the Selling Shareholder.

4. The Underwriting Agreement has been duly executed by each of the Company and the Selling Shareholder, and the Deposit Agreement has been duly executed by the Company.

5. The Mexican Underwriting Agreement has been duly executed by each of the Company and the Selling Shareholder, and the Mexican Underwriting Agreement constitutes the legal, valid and binding obligation of each of the Company and the Selling Shareholder, enforceable against each of the Company and the Selling Shareholder, in accordance with its terms.

6. The Series B Shares underlying the ADSs and the Mexican Shares to be sold by the Selling Shareholder pursuant to the Underwriting Agreement and the Mexican Underwriting Agreement, as applicable, have been duly issued by the Company and are fully paid and non-assessable, and when (i) such Series B Shares underlying the ADSs are deposited by the Selling Shareholder with the Depositary pursuant to the Deposit Agreement, and such ADSs are paid for and delivered, as set forth in the Underwriting Agreement, by the Underwriters, and (ii) the Mexican Firm Shares are paid for and delivered, as set forth in the Mexican Underwriting Agreement, by the Mexican Underwriters, title to such Series B Shares will be transferred to the Depositary pursuant to the terms of the Deposit Agreement and to the relevant ADSs will be transferred to the Underwriters and the Mexican Firm Shares will be transferred to the Mexican Underwriters, and such ADSs and Mexican Firm Shares will be free and clear of any liens, and not subject to any preemptive rights.

7. No authorization or approval by, and no notice to or filing with, any Mexican governmental authority is required for the execution and performance by the Company and the Selling Shareholder of the Underwriting Agreement, the Mexican Underwriting Agreement and the Deposit Agreement, for the deposit of Series B Shares by the Selling Shareholders with the Depositary or for the issuance against such deposited shares of ADRs evidencing the ADSs, except for the approval of the CNBV to undertake the public offering in Mexico of the Mexican Shares, which has been obtained and is in full force and effect.

8. The statements set forth in the Final Prospectus under the captions “Enforceability of Civil Liabilities,” Description of our Capital Stock,” and “Taxation,” insofar as such statements constitute a summary of Mexican law or a description of the terms of the bylaws of the Company, such statements fairly summarize Mexican law or contain a fair description of the bylaws of the Company in all material respects.

9. The choice of the laws of the State of New York, United States of America, as the governing law of each of the Underwriting Agreement and the Deposit Agreement is a valid choice of law.

10. The submission by each of the Company and the Selling Shareholder to the jurisdiction of the United States Federal and the New York State courts in the Borough of Manhattan in the City of New York included in the Underwriting Agreement, is a valid submission to jurisdiction, and the submission by the Company to the jurisdiction of the United States Federal and the New York State courts in the Borough of Manhattan in the City of New York included in the Deposit Agreement, is a valid submission to jurisdiction.

11. A judgment rendered by any United States Federal or New York State court located in the Borough of Manhattan in the City of New York, pursuant to a legal action instituted before any such court in connection with the Underwriting Agreement or the Deposit Agreement, would be enforceable against any of the Company or the

Selling Shareholder, as applicable, in the competent courts of Mexico, pursuant to Article 1347A of the Commerce Code (Código de Comercio), which provides, inter alia, that any judgment rendered outside Mexico may be enforced by Mexican courts, provided that:

(i)

such judgment is obtained in compliance with the legal requirements of the jurisdiction of the court rendering such judgment and in compliance with all legal requirements of any of the Underwriting Agreement or the Deposit Agreement;

(ii)

such judgment is strictly for the payment of a certain sum of money, based on an in personam (as opposed to an in rem) action;

(iii)

service of process was made personally on the defendant or on the appointed process agent;

(iv)

such judgment does not contravene Mexican law, public policy of Mexico, international treaties or agreements binding upon Mexico or generally accepted principles of international law;

(v)

the applicable procedure under the laws of Mexico with respect to the enforcement of foreign judgments (including the issuance of a letter rogatory by the competent authority of such jurisdiction requesting enforcement of such judgment and the certification of such judgment as authentic by the corresponding authorities of such jurisdiction in accordance with the laws thereof) is complied with;

(vi)

such judgment is final in the jurisdiction where obtained;

(vii)

the action in respect of which such judgment is rendered is not the subject matter of a lawsuit among the same parties pending before a Mexican court; and

(viii)

the courts of such jurisdiction recognize the principles of reciprocity in connection with the enforcement of judgments issued by a Mexican court in such jurisdiction.

12. To ensure the legality, validity or enforceability of each of the Underwriting Agreement and the Deposit Agreement, it is not necessary that any of the Underwriting Agreement or the Deposit Agreement be filed with any Mexican governmental authority, and the Underwriting Agreement is in proper legal form for the enforcement thereof against each of the Company and the Selling Shareholder and the Deposit Agreement is in proper legal form for the enforcement thereof against each of the Company.

13. Each of the Company and the Selling Shareholder have validly appointed CT Corporation System, as their respective agent for service of process, pursuant to the Underwriting Agreement and the Deposit Agreement.

14. Assuming that none of the Underwriters or the Depositary has or is deemed to have a permanent establishment in Mexico for tax purposes or is a resident of Mexico for tax purposes, under current Mexican law, no stamp or similar taxes, or withholding taxes, are payable by or on behalf of the Underwriters or the Depositary, in connection with (i) the sale of the ADSs as contemplated by the Underwriting Agreement, (ii) the execution or performance of each of the Underwriting Agreement or the Deposit Agreement, or (iii) the deposit of the Series B Shares that are to underlie the ADSs by the Selling Shareholder with the Depositary pursuant to the Deposit Agreement, and the issuance against such deposited Series B Shares of ADRs evidencing the ADSs.

The foregoing opinion is subject to the following qualifications:

(a) enforcement of each of the Underwriting Agreement, the Mexican Underwriting Agreement and the Deposit Agreement may be limited by bankruptcy, concurso mercantil, quiebra, insolvency, liquidation, reorganization, moratorium and other similar laws of general application relating to or affecting the rights of creditors generally;

(b) in any proceedings brought to the courts of Mexico for the enforcement of any of the Underwriting Agreement or the Deposit Agreement against the Company or the Selling Shareholder, as applicable, a Mexican court would apply Mexican procedural law in such proceedings;

(c) in the event that proceedings are brought to Mexico, seeking performance of the obligations of any of the Company or the Selling Shareholder, as applicable, under any of the Underwriting Agreement or the Deposit Agreement, as applicable, in Mexico, pursuant to the Mexican Monetary Law (Ley Monetaria de los Estados Unidos Mexicanos), each of the Company and the Selling Shareholder may discharge its obligations by paying any sums due in a currency other than Mexican currency, in Mexican currency at the rate of exchange prevailing in Mexico on the date when payment is made;

(d) provisions of each of the Underwriting Agreement, the Mexican Underwriting Agreement or the Deposit Agreement granting discretionary authority to the Representative, the Mexican Underwriters or the Depositary, as the case may be, cannot be exercised in a manner inconsistent with relevant facts, nor defeat any requirements from a competent authority to produce satisfactory evidence as to the basis of any determination; in addition, under Mexican law, each of the Company and the Selling Shareholder will have the right to contest in court any notice or certificate of the Representative, the Mexican Underwriters or the Depositary, as the case may be, purporting to be conclusive and binding;

(e) in the event that any legal proceedings are brought to the courts of Mexico, a Spanish translation of any documents in English required in such proceedings, prepared by a court-approved translator, would have to be approved by the court after the defendant had been given an opportunity to be heard with respect to the accuracy of the translation, and proceedings would thereafter be based upon the translated documents;

(f) in any bankruptcy proceeding initiated in Mexico, pursuant to the laws of Mexico, labor claims, claims of tax authorities for unpaid taxes, Social Security quotas, Workers’ Housing Fund quotas and Retirement Fund quotas may have priority over claims of the International Underwriters, the Mexican Underwriters or the Depositary;

(g) with respect to provisions contained in the Underwriting Agreement or the Deposit Agreement in connection with service of process, it should be noted that service of process by mail does not constitute personal service of process under Mexican law and, since such service of process is considered to be a basic procedural requirement, if for purposes of proceedings outside Mexico, service of process is made by mail, a final judgment based on such process would not be enforced by the courts of Mexico.

We are qualified to practice law in Mexico. We express no opinion as to any laws other than the laws of Mexico in effect on the date hereof or as to any matters not expressly covered herein. We express no opinion as to rights, obligations or other matters (including change of law or other circumstances) arising subsequent to the date hereof. We assume no responsibility to advise you of any change to our opinion subsequent to the date hereof.

This opinion is addressed to you solely for your benefit and it is not to be transferred to anyone else nor is it to be relied upon by anyone else or for any other purpose or quoted or referred to in any public document or filed with anyone without our express consent.

Very truly yours,

▇▇▇▇▇ ▇▇▇▇▇▇▇, S.C.

By __________________________

▇▇▇▇ ▇. ▇▇▇▇▇▇▇, a partner

EXHIBIT C-2

[Form of 10b-5 Letter of

▇▇▇▇▇ ▇▇▇▇▇▇▇, S.C., special Mexican counsel to the Company and the Selling Shareholder]

July 12, 2013

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated

Bank of America Tower

▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇,

as Representative of the several

Underwriters

Ladies and Gentlemen:

Because the primary purpose of our professional engagement was not to establish or confirm factual matters or financial, statistical or accounting matters, and because of the non-legal character of most of the statements contained in the Registration Statement, the Pricing Prospectus and the Final Prospectus, we are not passing upon and do not assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Registration Statement, the Pricing Prospectus and the Final Prospectus, and we make no representation that we have independently verified the accuracy, completeness or fairness of such statements. Without limiting the foregoing, we assume no responsibility for, and have not independently verified, the accuracy, completeness or fairness of the financial statements and schedules, statistics and other financial data included in the Registration Statement, the Pricing Prospectus and the Final Prospectus, and we have not examined the accounting, financial and statistical records from which such financial statements, schedules, statistics and financial data are derived.

However, in the course of our acting as special Mexican counsel to the Company and the Selling Shareholder in connection with the preparation of the Registration Statement, the Pricing Prospectus and the Final Prospectus, we participated in conferences and telephone conversations with officers and representatives of the Company and the Selling Shareholder, representatives of ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, United States counsel to the Company, ▇▇▇-▇▇▇▇▇▇, S.C., Mexican counsel to the Underwriters, and ▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, United States counsel to the Underwriters, during which conferences and conversations the contents of the Registration Statement, the Pricing Prospectus and the Final Prospectus were discussed, and carried out such further inquiries as we deemed necessary under the circumstances (including the review of certain documents supplied to us by the Company and the Selling Shareholder).

Based on our participation in the aforementioned conferences and conversations, our understanding of applicable Mexican law and policy, and the experience that we have gained in our practice in Mexico thereunder, we advise you that no information has come to our attention that causes us to believe that (i) the Registration Statement, at the time it became effective, or the Pricing Prospectus, including the documents incorporated by reference therein, considered together with the amount and the price to the public of the Securities on the front cover of the Final Prospectus, at 8:55 a.m. Eastern Standard time on July 9, 2013, contained any untrue statement of a material fact or omitted to state any material fact necessary, in order to make the statements therein, in light of the circumstances under which they were made, not misleading, or (ii) the Final Prospectus as of its date or as of the date hereof, contained or contains any untrue statement of a material fact or omitted or omits to state any material fact necessary, in order to make the statements therein, in light of the circumstances under which they were made, not misleading, other than, in all cases, the financial statements, schedules, financial data and statistical data deriving from the financial statements included therein, as to which we express no view. This letter shall, in no way, be construed as stating any view, express or implied, based upon the United States federal or state securities laws and the securities laws of any other jurisdiction other than Mexico, the interpretation thereof or the practice thereunder, with respect to which we have no knowledge or understanding; the language included above is included herein as a matter of convention only, but shall not be interpreted or construed as stating any view under the United States Securities Act of 1933.

We are furnishing this letter to you solely for your benefit. This letter is not to be used, circulated, quoted, relied upon or otherwise referred to for any other purpose.

Very truly yours,

▇▇▇▇▇ ▇▇▇▇▇▇▇, S.C.

By __________________________

▇▇▇▇ ▇. ▇▇▇▇▇▇▇, a partner

EXHIBIT D

[Form of Opinion of

▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ & Associates LLP, counsel for the Depositary]

▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ & Associates LLP

Counselors at Law

▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

(▇▇▇) ▇▇▇-▇▇▇▇

Telecopier (212) 319-7605

July 12, 2013

▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇

Incorporated

▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇

▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇

As Representative of the several Underwriters

named in Schedule 1 to the Underwriting Agreement

American Depositary Receipts

for American Depositary Shares

representing deposited Series B Shares of

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

Dear Sirs:

We are acting as counsel for JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), in connection with the Amended and Restated Deposit Agreement dated as of December 21, 2012 (the "Deposit Agreement") among Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. and its successors (the "Company"), the Depositary, and all holders from time to time of American Depositary Receipts issued hereunder ("ADRs"). We are delivering this opinion at the request of the Depositary to you pursuant to Section 8(d) of the Underwriting Agreement (the "Underwriting Agreement"), dated July 9, 2013 among the Company, Aeroinvest, S.A. de C.V., as selling shareholder, ▇▇▇▇▇▇▇ Lynch, Pierce, ▇▇▇▇▇▇ & ▇▇▇▇▇ Incorporated, as Representative of the Underwriters named in Schedule 1 thereto. Capitalized terms used herein but not otherwise defined herein shall have the meaning assigned to them in the Deposit Agreement.

In rendering the opinions set forth herein, we have examined such matters of fact and law as we have considered necessary or appropriate. We have examined the Deposit Agreement and originals, or photostatic or certified copies, of such records of JPMorgan Chase Bank, N.A., and such other documents as we have deemed relevant and necessary in rendering the opinions set forth herein. In such examination we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified or photostatic copies thereof and the authenticity of the originals of such copies.

Based upon the foregoing, and subject to the accuracy of the assumptions and to the qualifications and limitations herein stated, we are of the opinion that (i) the Deposit Agreement has been duly authorized, executed and delivered by the Depositary and constitutes a valid and legally binding obligation of the Depositary and is enforceable against the Depositary in accordance with its terms, except insofar as enforceability may be limited by (a) applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting creditors' rights generally and (b) general principles of equity (whether considered in an action at law or in equity) and (ii) when ADRs evidencing ADSs are issued in accordance with the Deposit Agreement against the deposit, pursuant to the terms of the Deposit Agreement, of duly authorized, validly issued, fully paid and nonassessable Shares of the Company, such ADRs will be validly issued and will entitle the Holders to the rights specified therein and in the Deposit Agreement. We express no opinion, however, as to Section 16 of the Deposit Agreement.

In expressing the opinions set forth herein, we have assumed that (i) the Deposit Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and legally binding obligation of the Company enforceable against it in accordance with its terms, (ii) the Shares have been duly deposited with the Custodian under and in accordance with all applicable laws and regulations, (iii) all signatures on documents examined by us have been validly authorized by appropriate corporate authorization procedure, and (iv) that the choice of New York law contained in the Deposit Agreement is legal and valid under the laws of the United Mexican States and all other relevant jurisdictions and that insofar as any obligation under the Deposit Agreement is to be performed in, or by a party organized under the laws of, any jurisdiction outside of the United States of America, its performance will not be illegal or ineffective in any jurisdiction by virtue of the law of that jurisdiction.

In rendering the foregoing opinion, we are passing only upon matters arising under the laws of the State of New York and we express no opinion as to the laws of any other jurisdiction.

Our opinions are limited to the date hereof, and we do not in any event undertake to advise you of any facts or circumstances occurring or coming to our attention subsequent to the date hereof.

This opinion letter is not to be circulated, used, quoted or otherwise referred to for any purpose other than in connection with the offering of the ADRs evidencing the ADSs, which offering is being made pursuant to the Underwriting Agreement.

Very truly yours,

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. 36,000,000 Series B Shares (without par value) of Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. directly or in the form of American Depositary Shares UNDERWRITING AGREEMENT

Document Metadata

Document Metadata

Table of Contents